FDA Calendar

Biotech Stock Catalyst and FDA Calendar for your biotech stock investing. Use our tools on your road to profit in the stock market. Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA, Advisory Committee and Phase 2 & 3 trial data releases dates.

Refer to the Biotech Historical Catalyst Calendar for completed biotech stock catalysts.

The catalyst date is the LATEST expected date for the catalyst to occur by. For example, if the catalyst date is 12/31/17, the event is expected to occur BY 12/31/17. It does NOT necessarily mean that the catalyst will occur ON this date. In most cases it will occur BEFORE.

Please refer to the "FDA Calendar Glossary" for a list of terms used in the FDA Decision Calendar.

LARGE CAP CATALYSTS - generally only Phase 3 catalysts noted in company presentations and/or earnings releases are shown.

PDUFA DATES - biosimilars and sNDA/sBLA filings and resubmissions are only noted if a PDUFA date has been released by the company. No official PDUFA date = No entry (e.g. Saxagliptin and dapagliflozin resubmission). Standard reviews for NDA/BLA filings use a 10 month estimate following filing acceptance for a NEW MOLECULAR ENTITY if no PDUFA date has been announced.

Pipeline data are current and updated daily! Click on the date for the source of the catalyst.

Financial data are delayed 15-35 minutes.

Subscribe HERE to ensure you receive your weekly FREE copy of the BioPharmCatalyst Biotech Stock Watch list and/or our daily option of Biotech Stock Price Movers and Pipeline Database updates.

Showing 563 drugs

Ticker	Price	Drug	Stage	Catalyst
ADMS	$14.02 +0.34 (+2.48%)	ADS-5102 Levodopa-Induced Dyskinesia	PDUFA	08/24/2017 PDUFA date August 24, 2017.
NVO	$45.34 -0.6 (-1.3%)	Victoza (liraglutide) Type 2 diabetes	PDUFA	08/25/2017 FDA Advisory Committee voted 17-2 vote from that Victoza provides substantial evidence of cardiovascular risk reduction. PDUFA date. sNDA filing announced October 25, 2017 - 10 month timeline would render a PDUFA date of on or about August 25, 2017.
KMDA	$4.45 +0.2 (+4.7%)	KamRAB Prophylaxis of rabies disease	PDUFA	08/29/2017 PDUFA date August 29, 2017.
MDCO	$35.40 -1.26 (-3.44%)	Meropenem-vaborbactam Complicated urinary tract infections (cUTI)	PDUFA priority review	08/29/2017 PDUFA date under priority review August 29, 2017.
ANTH	$1.26 -0.03 (-2.33%)	Blisibimod IgA nephropathy	Phase 2	08/31/2017 Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due August 2017.
BLPH	$1.13 +0.02 (+1.8%)	INOpulse delivery device Pulmonary Hypertension associated with COPD (PH-COPD)	Phase 2	08/31/2017 Phase 2 initiated 3Q 2016. Noted August 7, 2017 that data are due "shortly". BPC estimate end of August as latest likely date.
VSTM	$3.15 -0.09 (-2.78%)	Duvelisib - DUO Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)	Phase 3	08/31/2017 Phase 3 data due late summer 2017.
MYL	$30.56 +0.09 (+0.29%)	MYL-1401O - trastuzumab biosimilar Trastuzumab biosimilar	PDUFA	09/03/2017 PDUFA date September 3, 2017. Advisory Committee Meeting July 13, 2017 voted 16-0 recommending approval.
AGN	$224.77 -3.22 (-1.42%)	Liletta Prevention of pregnancy	PDUFA	09/04/2017 sNDA accepted January 4, 2017. PDUFA estimate September 4, 2017.
ARRY	$8.78 -0.2 (-2.23%)	Binimetinib - COLUMBUS BRAF mutant melanoma cancer	NDA Filing	09/09/2017 Phase 3 data released September 26, 2016 met primary endpoint. Data from Part 2 portion of trial due released May 9, 2017 with presentation at ESMO September 9 , 2017. NDA filing announced June 5, 2017.
ARRY	$8.78 -0.2 (-2.23%)	Encorafenib and cetuximab - BEACON CRC BRAF-Mutant Colorectal Cancer	Phase 3	09/09/2017 Phase 3 initiated June 2016. SPA announced September 2016. Randomization part of trial now enrolling. Data from the safety lead-in due at ESMO September 9, 2017.
NKTR	$18.42 -1.11 (-5.64%)	NKTR-214 Solid tumors - cancer	Phase 1/2	09/09/2017 Phase 1/2 initial data released at ASCO June 5, 2017. Poster at ESMO September 9, 2017.
MGNX	$15.83 -0.57 (-3.42%)	Flotetuzumab AML/MDS	Phase 1	09/10/2017 Phase 1 interim data due at oral presentation at ESMO September 10, 2017.
FPRX	$28.50 -0.01 (-0.04%)	FP-1039 Mesothelioma cancer	Phase 1b	09/11/2017 Phase 1b NSCLC halted, mesothelioma to continue. Data due at ESMO 8-12 September 2017. Exact date TBC.
IMMU	$7.98 +0.2 (+2.57%)	SACITUZUMAB GOVITECAN Urothelial cancer	Phase 2	09/12/2017 Phase 2 interim data due at ESMO September 8-12, 2017.
TSRO	$109.05 -3.94 (-3.49%)	Niraparib - AVANOVA Ovarian cancer	Phase 1/2	09/12/2017 Phase 1/2 data due at ESMO September 8-12, 2017.
TSRO	$109.05 -3.94 (-3.49%)	Niraparib and Keytruda (TOPACIO) Triple-negative Breast Cancer or Ovarian Cancer	Phase 1/2	09/12/2017 Phase 1/2 enrolling. Initial data presented at ASCO investor event. ORR 4/13 patients. Further data due at ESMO September 8-12, 2017.
GSK	$39.05 -0.19 (-0.49%)	Shingrix Shingles	PDUFA	09/13/2017 BLA filing announced October 24, 2016. PDUFA estimate October 24, 2017. Advisory Committee Meeting September 13, 2017.
GTXI	$5.68 +0.05 (+0.88%)	Enobosarm Postmenopausal women with stress urinary incontinence (SUI)	Phase 2	09/13/2017 Phase 2 initiated January 2016. Data to be presented at International Continence Society Annual Meeting, September 13, 2017.
AGN	$224.77 -3.22 (-1.42%)	ABP 215 Biosimilar candidate to Avastin (bevacizumab)	PDUFA	09/14/2017 BsUFA (PDUFA) date September 14, 2017. Advisory Committee meeting July 13, 2017.
AMGN	$167.81 -3.58 (-2.09%)	ABP 215 Biosimilar candidate to Avastin (bevacizumab)	PDUFA	09/14/2017 BsUFA (PDUFA) date September 14, 2017.
MDWD	$6.00 -0.3 (-4.77%)	EscharEx Chronic and other hard-to-heal wounds	Phase 2	09/15/2017 Phase 2 data released early February 2016. Primary endpoint met. Secondary endpoint of time to complete debridement not met. Top-line data from second cohort due early September 2017. September noted as last possible date for BPC database purposes only. Pivotal trial planned for 1H 2018.
NEOS	$6.70 +0 (+0%)	NT-0201 Attention deficit hyperactivity disorder (ADHD)	PDUFA	09/15/2017 PDUFA date September 15, 2017.
GSK	$39.05 -0.19 (-0.49%)	FF/UMEC/VI Chronic obstructive pulmonary disease (COPD)	PDUFA	09/21/2017 Filing announced Novermber 21, 2016. PDUFA estimate September 21, 2017.
INVA	$12.51 -0.13 (-1.03%)	FF/UMEC/VI Chronic obstructive pulmonary disease (COPD)	PDUFA	09/21/2017 Filing announced November 21, 2016. PDUFA estimate September 21, 2017.
MRK	$61.84 -0.86 (-1.38%)	Keytruda Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma	PDUFA priority review	09/22/2017 PDUFA date under priority review Sept. 22, 2017.
JNJ	$133.04 -1.13 (-0.85%)	Sirukumab Rheumatoid arthritis	PDUFA	09/23/2017 BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
BMY	$56.77 -0.73 (-1.27%)	Opdivo (CM-040) Previously Treated Hepatocellular Carcinoma	PDUFA priority review	09/24/2017 PDUFA date under priority review September 24, 2017.
IPCI	$0.97 +0.01 (+1.04%)	Rexista Pain relief	PDUFA	09/25/2017 PDUFA date September 25, 2017. Advisory Committee Meeting July 26, 2017 voted 22-1 against recommending approval.
PTCT	$17.56 -0.13 (-0.74%)	Translarna Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)	PDUFA	09/28/2017 Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. New PDUFA date October 24, 2017. Advisory Committee Meeting September 28, 2017.
NVO	$45.34 -0.6 (-1.3%)	Fast-acting insulin aspart Type 1 and type 2 diabetes	PDUFA	09/29/2017 NDA filing resubmission noted March 29, 2017 in response to CRL issued October 2016. Estimated latest possible PDUFA date - September 29, 2017 using 6-month timeline. Waiting for official date from company.
NVS	$83.18 -1.19 (-1.42%)	CTL019 Relapsed/Refractory B-Cell Acute lymphoblastic leukemia	PDUFA priority review	09/29/2017 PDUFA date under priority review announced March 29, 2017. No date given. Assume 6-month review - September 29, 2017. Advisory Committee Meeting July 12, 2017 voted 10-0 recommending approval.
ABBV	$69.85 -0.57 (-0.81%)	ABT-494 - SELECT-BEYOND Rheumatoid arthritis	Phase 3	09/30/2017 Phase 3 top-line data due likely 3Q 2017.
ABUS	$3.60 -0.1 (-2.71%)	Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR	Phase 3	09/30/2017 Phase 3 top-line data due 3Q 2017.
ABUS	$3.60 -0.1 (-2.71%)	ARB-1467 Hepatitis B (HBV)	Phase 2	09/30/2017 Phase 2 Cohort 4 data due September 2017.
ALDX	$4.30 +0.05 (+1.17%)	ADX-102 Dry eye syndrome	Phase 2a	09/30/2017 Phase 2a completion of dosing announced July 18, 2017. Data due September 2017.
ALNY	$80.28 -1.07 (-1.32%)	Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR	Phase 3	09/30/2017 Phase 3 top-line data due 3Q 2017.
AVEO	$3.03 -0.06 (-1.95%)	TIVO-3 - tivozanib Third line treatment of patients with renal cell cancer	Phase 3	09/30/2017 Phase 3 completion of enrollment noted June 20, 2017. Futility analysis due August or September, 2017. Top-line data due 1Q 2018.
AXON	$21.05 -0.75 (-3.45%)	Intepirdine - MINDSET Alzheimer's disease	Phase 3	09/30/2017 Phase 3 data are due late September 2017.
AXSM	$4.95 -0.05 (-1%)	AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions	Phase 3	09/30/2017 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AZRX	$3.82 +0.06 (+1.59%)	MS1819-SD Exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP)	Phase 2	09/30/2017 Announced December 21, 2016 that Phase 2 enrollment has commenced. Trial completion due 3Q 2017.
BMY	$56.77 -0.73 (-1.27%)	CM-511 – Opdivo + Yervoy First-line Melanoma	Phase 3	09/30/2017 Phase 3 data due 2Q or 3Q 2017.
FCSC	$2.50 -0.08 (-3.11%)	FCX-007 Recessive dystrophic epidermolysis bullosa	Phase 1/2	09/30/2017 Phase 1/2 initiation of dosing announced February 23, 2017. Phase 1 data due 3Q 2017.
FOLD	$12.29 -0.31 (-2.47%)	SD-101 Epidermolysis Bullosa (EB)	Phase 3	09/30/2017 "Phase 3 enrollment completed April 3, 2017 with top-line data due late 3Q 2017. "
FOLD	$12.29 -0.31 (-2.47%)	ATB200 Pompe Disease	Phase 1/2	09/30/2017 Phase 1/2 additional data released February 15, 2017. Further data released May 15, 2017. Full data due late 3Q 2017.
GILD	$72.34 -1.01 (-1.38%)	GS-0976 Nonalcoholic steatohepatitis (NASH)	Phase 2	09/30/2017 Phase 2 data due 3Q 2017.
GTXI	$5.68 +0.05 (+0.88%)	Enobosarm Breast cancer - metastatic or locally advanced, ER+/AR+ breast cancer	Phase 2	09/30/2017 Phase 2 initial data released December, 8 2016. Top-line data due 3Q 2017.
INSM	$12.05 +0.34 (+2.9%)	ARIKAYCE Non-tuberculous Mycobacterial Lung Disease	Phase 3	09/30/2017 Phase 3 data due September, 2017 +/- one month.
MRNS	$2.89 -0.1 (-3.35%)	Ganaxolone CDKL5 disorder	Phase 2	09/30/2017 Phase 2 preliminary CDKL5 cohort data released January 23, 2017. Top-line data due 3Q 2017.
NBRV	$8.83 -0.54 (-5.77%)	Lefamulin - LEAP 1 Moderate to severe Community Acquired Bacterial Pneumonia (CABP)	Phase 3	09/30/2017 Phase 3 data due September 2017.
NKTR	$18.42 -1.11 (-5.64%)	Inhaled Amikacin Solution (BAY41-6551T) Gram-Negative Pneumonia (INHALE 1)	Phase 3	09/30/2017 Phase 3 data due 3Q 2017.
OTIC	$18.85 -0.5 (-2.59%)	OTO-104 AVERTS-1 Ménière's disease	Phase 3	09/30/2017 Second Phase 3 trial initiated March 2016. Data due September 2017.
PFE	$32.95 -0.41 (-1.23%)	Mylotarg (gemtuzumab ozogamicin) Acute myeloid leukemia (AML)	PDUFA	09/30/2017 Advisory Committee Meeting July 11, 2017 voted in favor 6-1 of a favorable risk:benefit profile. PDUFA date September 2017 for BLA resubmission. Exact date not provided, assume latest possible date is September 30 solely for purposes of entry into the BPC PDUFA Calendar (likely to be before).
PRQR	$4.35 -0.6 (-12.13%)	QR-010 Cystic Fibrosis	Phase 1b	09/30/2017 Phase 1b top-line data due September 2017.
RDHL	$8.77 +0.23 (+2.69%)	BEKINDA IBS-D	Phase 2	09/30/2017 Phase 2 top-line data due September 2017.
REGN	$464.02 -4.52 (-0.97%)	Dupixent (dupilumab) - LIBERTY ASTHMA QUEST Asthma	Phase 3	09/30/2017 Phase 3 data due 3Q 2017.
SAGE	$81.25 -3.06 (-3.63%)	SAGE-547 SRSE	Phase 3	09/30/2017 Phase 3 data due 3Q 2017 - updated timeline received May 9, 2017. Previous guidance was for data release 2Q 2017.
SNY	$48.08 -0.35 (-0.73%)	Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR	Phase 3	09/30/2017 Phase 3 top-line data due 3Q 2017.
SNY	$48.08 -0.35 (-0.73%)	Dupixent (dupilumab) - LIBERTY ASTHMA QUEST Asthma	Phase 3	09/30/2017 Phase 3 data due 3Q 2017.
VBLT	$5.15 +0.2 (+4.04%)	VB-111 Recurrent glioblastoma (rGBM) cancer	Phase 3	09/30/2017 Phase 3 completion of enrollment announced January 6, 2017. Interim analysis due late September 2017. Top-line data due 1Q 2018.
VNDA	$16.05 -0.25 (-1.54%)	Tradipitant Chronic pruritus in patients with atopic dermatitis	Phase 2	09/30/2017 Phase 2 data due 3Q 2017.
VRX	$14.34 +0.19 (+1.34%)	SAN-300 Rheumatoid Arthritis	Phase 2	09/30/2017 Phase 2 data due 1H 2017 according to latest company guidance. Timeline has passed so assume data release 3Q 2017.
VSAR	$16.50 -0.15 (-0.91%)	VRS-317 VELOCITY Growth hormone deficiency, or GHD - pediatric	Phase 3	09/30/2017 Phase 3 top-line data due September 2017.
ZGNX	$12.05 +0.45 (+3.87%)	ZX008 - (Study 1) Dravet syndrom	Phase 3	09/30/2017 Phase 3 data due 3Q 2017.
ZYNE	$6.32 -0.04 (-0.63%)	ZYN002 Fragile X syndrome	Phase 2	09/30/2017 Phase 2 trial initiation announced January 3, 2017. Data are due September 2017.
FLXN	$22.04 -0.23 (-1.04%)	Zilretta - FX006 Osteoarthritis of the knee	PDUFA	10/06/2017 PDUFA date October 6, 2017.
MYL	$30.56 +0.09 (+0.29%)	MYL-1401H Neulasta biosimilar	PDUFA	10/09/2017 PDUFA date October 9, 2017.
ACRX	$3.00 +0 (+0%)	ARX-04 (SAP303) Moderate-to-severe acute pain following a surgical procedure	PDUFA	10/12/2017 PDUFA date October 12, 2017. Noted June 7, 2017 that an Advisory Committee Meeting is no longer planned.
FENCF	$7.01 +0.21 (+3.02%)	Sodium Thiosulphate Cisplatin-induced ototoxicity	Phase 3	10/14/2017 Phase 3 data due October 14th at SIOP conference.
NBIX	$53.12 -0.43 (-0.81%)	INGREZZA Tardive dyskinesia	PDUFA	10/14/2017 PDUFA date for sNDA 80 mg capsules October 14, 2017.
JNJ	$133.04 -1.13 (-0.85%)	STELARA (USTEKINUMAB) Plaque psoriasis	PDUFA	10/15/2017 sBLA filing announced December 15, 2016. PDUFA estimate October 15, 2017.
ATRS	$3.06 +0.04 (+1.32%)	Makena - auto injector Preterm birth	PDUFA	10/17/2017 sNDA filing announced April 17, 2017. PDUFA date October 17, 2017 assuming 6-month priority review.
ATRS	$3.06 +0.04 (+1.32%)	VIBEX QuickShot Testosterone deficiency	PDUFA	10/20/2017 PDUFA date October 20, 2017.
EIGR	$7.80 -0.2 (-2.5%)	Pegylated Interferon Lambda (LIMT HDV) Hepatitis delta virus (HDV)	Phase 2	10/20/2017 Noted July 24, 2017 that enrollment has been completed. Interim data due at AASLD, October 20 -24, 2017.
JNJ	$133.04 -1.13 (-0.85%)	SIMPONI ARIA Psoriatic arthritis (PsA)	PDUFA	10/21/2017 sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
JNJ	$133.04 -1.13 (-0.85%)	SIMPONI ARIA Ankylosing Spondylitis	PDUFA	10/21/2017 sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
ALXN	$134.63 -1.92 (-1.41%)	Eculizumab Refractory generalized myasthenia gravis (gMG)	PDUFA	10/23/2017 (sBLA) PDUFA date October 23, 2017.
TSRO	$109.05 -3.94 (-3.49%)	Rolapitant - intravenous (IV) Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients	PDUFA	10/25/2017 CRL January 11 2017. Resubmission noted with new PDUFA October 25, 2017.
JNJ	$133.04 -1.13 (-0.85%)	XARELTO (rivaroxaban) Reduce the Risk of Recurrent Venous Thromboembolism (VTE)	PDUFA priority review	10/28/2017 PDUFA date under priority review October 28, 2017.
EGRX	$56.02 +0.25 (+0.44%)	Ready-to-dilute (RTD) Pemetrexed Injection Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma	PDUFA	10/30/2017 PDUFA date October 30, 2017.
KPTI	$8.15 -0.27 (-3.21%)	Selinexor - SEAL Dedifferentiated liposarcoma	Phase 2/3	10/31/2017 Phase 2/3 trial initiated January 2016. Top-line data for the Phase 2 portion due September or October 2017.
PRTA	$55.23 -2.46 (-4.27%)	PRX003 Psoriatic Arthritis	Phase 1b	10/31/2017 Phase 1b data due October 2017.
SYRS	$20.20 -0.73 (-3.49%)	SY-1425 Relapsed or refractory Acute myeloid leukemia (AML) and relapsed high-risk Myelodysplastic Syndrome (MDS) - cancer	Phase 2	10/31/2017 Phase 2 initiated September 2016. Preliminary data due fall of 2017.
KERX	$6.73 -0.17 (-2.47%)	Auryxia Iron deficiency anemia in non-dialysis dependent CKD patients	PDUFA	11/06/2017 (sNDA) PDUFA date November 6, 2017.
BMY	$56.77 -0.73 (-1.27%)	Sprycel (dasatinib) Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia	PDUFA priority review	11/09/2017 PDUFA date under priority review for sNDA of November 9, 2017.
DVAX	$16.40 -0.25 (-1.51%)	HEPLISAV-B Hepatitis B	PDUFA	11/10/2017 CRL February 25, 2013 and November 14, 2016. Original PDUFA date set for August 10, 2017 but noted August 3, 2017 a 3-month extension to August 10.. Advisory Committee Meeting July 28, 2017 voted 21 -1 in favor of recommending approval.
HRTX	$15.25 -0.15 (-0.98%)	CINVANTI (HTX-019) Prevention of chemotherapy-induced nausea and vomiting (CINV)	PDUFA	11/12/2017 PDUFA date November 12, 2017.
ARDX	$4.45 -0.3 (-6.32%)	Tenapanor (T3MPO-2) Constipation-predominant irritable bowel syndrome (IBS-C)	Phase 3	11/15/2017 Phase 3 data due early 4Q 2017. Estimate November 15, 2017 as latest possible date using company guidance of "early 4Q".
RARE	$57.95 -3.39 (-5.53%)	rhGUS Mucopolysaccharidosis 7 (MPS 7)	PDUFA priority review	11/16/2017 Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. PDUFA date under priority review November 16, 2017.
KITE	$126.03 -2.06 (-1.61%)	Axicabtagene ciloleucel (KTE-C19) - ZUMA-1 Refractory Non-Hodgkin's Lymphoma (NHL) - cancer	PDUFA priority review	11/29/2017 PDUFA date under priority review November 29, 2017.
CLDX	$2.36 -0.05 (-2.08%)	Glembatumumab vedotin, varlilumab, Opdivo or Keytruda Cancer - melanoma	Phase 2	11/30/2017 Phase 2 continues to enroll. Glembatumumab vedotin and varlilumab arm data due fall of 2017.
AMGN	$167.81 -3.58 (-2.09%)	Repatha Cardiovascular disease	PDUFA	12/02/2017 Phase 3 cardiovascular outcomes study data released March 17, 2017 - endpoints met but down on expectations. PDUFA date under priority review December 2, 2017.
GSK	$39.05 -0.19 (-0.49%)	Dolutegravir + rilpivirine: HIV	PDUFA priority review	12/05/2017 Primary endpoint of non inferiority met - December 19, 2016. NDA filing announced June 5, 2017. Priority review requested - estimate PDUFA December 5, 2017 (6 month timeline) assuming priority review granted.
JNJ	$133.04 -1.13 (-0.85%)	Rilpivirine and Dolutegravir HIV	PDUFA priority review	12/05/2017 Primary endpoint of non inferiority met - December 19, 2016. NDA filing announced June 5, 2017. Priority review requested - estimate PDUFA December 5, 2017 (6 month timeline) assuming priority review granted.
NVO	$45.34 -0.6 (-1.3%)	Semaglutide Type 2 diabetes	PDUFA	12/05/2017 NDA filed December 5, 2016. PDUFA estimate December 5, 2017.
BLUE	$93.25 -3.85 (-3.97%)	LentiGlobin - HGB-206 Sickle disease	Phase 1/2	12/09/2017 Update at ASH 2016. Further data due at ASH 2017. Exact date TBC.
IMDZ	$8.15 -0.2 (-2.4%)	G100 Follicular non-Hodgkin Lymphoma - cancer	Phase 2	12/09/2017 Phase 2 data at ASCO 2017 (June 2, 2017). Also due at ASH 2017.
SGEN	$46.37 -0.8 (-1.7%)	ADCETRIS Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma	PDUFA priority review	12/16/2017 PDUFA date under Priority review for sBLA filing December 16, 2017.
ACRS	$25.26 -1.33 (-5.01%)	A-101 Seborrheic keratosis (SK)	PDUFA	12/24/2017 PDUFA date is December 24, 2017
AGRX	$3.48 +0.05 (+1.45%)	Twirla Contraceptive patch	PDUFA	12/26/2017 CRL issued 2013. Phase 3 top-line data released January 3, 2017 - poor data. NDA resubmitted with PDUFA date of December 26, 2017
CORI	$7.62 -0.05 (-0.66%)	Twirla Contraceptive patch	PDUFA	12/26/2017 Phase 3 top-line data released January 3, 2017 - poor data. NDA resubmitted by partner Agile Therapeutics with PDUFA date of December 26, 2017
VRX	$14.34 +0.19 (+1.34%)	Luminesse Eye Brightener	PDUFA	12/27/2017 PDUFA date December 27, 2017.
AEZS	$1.87 -0.08 (-4.11%)	Macimorelin Acetate - Macrilen Adult Growth Deficiency	PDUFA	12/30/2017 CRL issued November 2014. Phase 3 data released January 4, 2017 - trial failed. NDA resubmitted with new PDUFA date of December 30, 2017.
ABBV	$69.85 -0.57 (-0.81%)	Imbruvica - PHOENIX First-line Diffuse large B-cell lymphoma (DLBCL)	Phase 3	12/31/2017 Phase 3 interim data possibly due 2H 2017.
ABBV	$69.85 -0.57 (-0.81%)	Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)	Phase 3	12/31/2017 Phase 3 data due 2017 as per 1Q earnings call.
ABBV	$69.85 -0.57 (-0.81%)	Risankizumab Psoriasis	Phase 3	12/31/2017 Phase 3 data due by the end of 2017.
ABBV	$69.85 -0.57 (-0.81%)	Elagolix Uterine Fibroids	Phase 3	12/31/2017 Phase 3 initiated in January 2016. Data due late 2017.
ABBV	$69.85 -0.57 (-0.81%)	Risankizumab Psoriatic Arthritis	Phase 2b	12/31/2017 Phase 2b data due 2017.
ABBV	$69.85 -0.57 (-0.81%)	Rova-T (TRINITY) Third-line Small Cell Lung Cancer	Phase 2	12/31/2017 Phase 2 pivotal data due 2017.
ABBV	$69.85 -0.57 (-0.81%)	ABT-494 Atopic Dermatitis	Phase 2b	12/31/2017 Phase 2b data due 2017.
ACHN	$4.88 +0 (+0%)	JNJ-4178 - OMEGA-1 Hepatitis C (HCV)	Phase 2b	12/31/2017 Phase 2b trial initiation announced November 30, 2016. Data due 2H 2017.
ADRO	$11.10 -0.2 (-1.77%)	CRS-207 with pembrolizumab Mesothelioma - cancer	Phase 2	12/31/2017 Phase 2 trial to be initiated 2Q 2017 with early data due 2H 2017.
ADXS	$6.07 -0.03 (-0.5%)	Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer	Phase 1/2	12/31/2017 Phase 1/2 updated data due 2H 2017.
ADXS	$6.07 -0.03 (-0.5%)	Axalimogene filolisbac Anal cancer (FAWCETT)	Phase 2	12/31/2017 Phase 2 initiated June 2016. Preliminary update due 2H 2017.
AFMD	$2.05 +0 (+0%)	AFM13 with Keytruda Hodgkin Lymphoma - Cancer	Phase 1b	12/31/2017 Phase 1b update 2H 2017.
AGIO	$54.89 -1.33 (-2.37%)	AG-120 IDH1m Relapsed/Refractory AML - cancer	NDA Filing	12/31/2017 NDA filing due by end of 2017.
AGN	$224.77 -3.22 (-1.42%)	Cortisol Analog Dry Eye disease	Phase 3	12/31/2017 Phase 3 trial to be initiated 2H 2017.
AKAO	$17.89 -0.27 (-1.49%)	Plazomicin - CARE Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)	NDA Filing	12/31/2017 Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
ALKS	$50.92 -0.64 (-1.25%)	ALKS 8700 Multiple sclerosis (MS)	Phase 3	12/31/2017 Phase 3 initiation announced March 16, 2017. Completion expected by end of 2017.
ANAB	$21.29 +0.03 (+0.14%)	ANB020 Moderate-to-severe adult atopic dermatitis	Phase 2	12/31/2017 Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
ANAB	$21.29 +0.03 (+0.14%)	ANB020 Severe adult peanut allergy	Phase 2a	12/31/2017 Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
ARDX	$4.45 -0.3 (-6.32%)	RDX7675 Hyperkalemia	Phase 2	12/31/2017 Onset of action trial data due 4Q 2017.
ARGS	$0.20 -0.02 (-7.91%)	rocapuldencel-T (AGS-003) Early stage renal cell carcinoma (RCC) - cancer	Phase 2	12/31/2017 Phase 2 trial initial data due 2H 2017.
ARGX	$20.35 -0.32 (-1.55%)	ARGX-110 Relapsed/refractory cutaneous T-cell lymphoma (CTCL)	Phase 2	12/31/2017 Phase 2 interim data due by the end of 2017 with top-line data due by the end of 2018.
ARGX	$20.35 -0.32 (-1.55%)	ARGX-110 Acute myeloid leukemia (AML)	Phase 1/2	12/31/2017 Phase 1/2 interim data due by the end of 2017.
AST	$3.00 -0.2 (-6.25%)	AST-OPC1 SCiSTAR Cervical spinal cord injury	Phase 1/2	12/31/2017 Phase 1/2 six and nine-month data released January 24, 2017. 10 and 20 million cell cohort 6-month top-line data due January 2018. Cohort 2 12-month data due later in 2017.
ATNM	$0.60 +0 (+0%)	Actimab-A Acute Myeloid Leukemia (AML)	Phase 2	12/31/2017 Phase 2 to initiated September 2016. Interim analysis due 2H 2017.
ATNX	$15.51 -1.11 (-6.63%)	Oraxol Metastatic breast cancer	Phase 3	12/31/2017 Phase 3 interim data due 2017.
AXON	$21.05 -0.75 (-3.45%)	Intepirdine - HEADWAY-DLB Dementia with Lewy bodies (DLB)	Phase 2b	12/31/2017 Phase 2b data due 4Q 2017
AXON	$21.05 -0.75 (-3.45%)	Nelotanserin Visual hallucinations in subjects with Lewy body dementia	Phase 2	12/31/2017 Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Top-line data due 4Q 2017.
AXSM	$4.95 -0.05 (-1%)	AXS-02 CREATE-1 Complex regional pain syndrome (CRPS)	Phase 3	12/31/2017 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AZN	$29.08 -0.1 (-0.35%)	Tralokinumab (STRATOS2) Severe, uncontrolled asthma	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
AZN	$29.08 -0.1 (-0.35%)	Moxetumomab Cancer - leukaemia	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
AZN	$29.08 -0.1 (-0.35%)	Durvalumab +/- tremelimumab (ARCTIC) Lung cancer	Phase 3	12/31/2017 Phase 3 data 2H 2017.
AZN	$29.08 -0.1 (-0.35%)	Bydureon Type 2 Diabetes	Phase 3	12/31/2017 Phase 3 Cardiovascular Outcome trial data due 2H 2017.
AZN	$29.08 -0.1 (-0.35%)	Benralizumab Severe, uncontrolled asthma	PDUFA	12/31/2017 PDUFA 4Q 2017. Exact data not confirmed. 12/31/2017 used solely for entry into the BioPharmCatalyst database. Actual date will most likely be BEFORE.
BIIB	$284.42 -9.66 (-3.29%)	BAN2401 (Aβ mAb) Alzheimer’s disease	Phase 2	12/31/2017 Phase 2 data due by the end of 2017.
BIIB	$284.42 -9.66 (-3.29%)	BG00011 (STX-100) Idiopathic pulmonary fibrosis (IPF)	Phase 2	12/31/2017 Phase 2 to be completed 2017.
BLRX	$1.13 +0.01 (+0.89%)	BL-8040 in combination with KEYTRUDA - COMBAT trial Pancreatic cancer	Phase 2	12/31/2017 Phase 2 initiated September 2016. Partial data due 2H 2017. Full data due 2H 2018.
BLRX	$1.13 +0.01 (+0.89%)	BL-8040 Mobilization and collection of bone marrow stem cells	Phase 2	12/31/2017 Phase 2 trial initiated March 2016. Partial data released March 20, 2017 with topline results by the end of 2017 with Phase 2/3 trial to be initiated 2H 2017.
BLUE	$93.25 -3.85 (-3.97%)	Lenti-D - Starbeam Childhood cerebral adrenoleukodystrophy (CCALD)	Phase 2/3	12/31/2017 Phase 2/3 trial initiated October 2013. Interim data released at AAN Conference April 20, 2016. Full data due by the end of 2017.
BMY	$56.77 -0.73 (-1.27%)	CM-459 – Opdivo First-line Hepatocellular carcinoma (HCC) - cancer	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
BMY	$56.77 -0.73 (-1.27%)	CM-227 – Opdivo + Yervoy First-line Non-small cell lung cancer (NSCLC)	Phase 3	12/31/2017 Phase 3 interim data due 4Q 2017. Primary completion 1Q 2018.
BOLD	$18.50 +0.46 (+2.54%)	AT342 - VALENS Crigler-Najjar	Phase 1/2	12/31/2017 Phase 1/2 preliminary data due 4Q 2017.
BOLD	$18.50 +0.46 (+2.54%)	AT132 - ASPIRO X-Linked Myotubular Myopathy	Phase 1/2	12/31/2017 Phase 1/2 preliminary data due 4Q 2017.
BPTH	$0.27 -0.01 (-5%)	BP-1001 Acute myeloid leukemia (AML)	Phase 2	12/31/2017 Phase 2 first patient enrolled November 2016. Interim analysis due by the end of 2017.
BTX	$2.51 -0.06 (-2.34%)	AST-OPC1 - SCiStar Cervical spinal cord injury	Phase 1/2	12/31/2017 Phase 1/2 six and nine-month data released January 24, 2017. 10 and 20m cell cohort 6-month top-line data due January 2018. Cohort 2 12-month data due later in 2017.
BYSI	$38.41 -0.84 (-2.15%)	Plinabulin (Trial 106) Prevention of neutropenia	Phase 2/3	12/31/2017 First data due 2H 2017.
BYSI	$38.41 -0.84 (-2.15%)	Plinabulin (Trial 105) Prevention of neutropenia	Phase 2/3	12/31/2017 Phase 2/3 enrollment announced April 25, 2017. Data from Phase 2 portion due 2H 2017. Interim data from Phase 3 portion due 1H 2018.
CALA	$13.95 -0.45 (-3.13%)	CB-839 with paclitaxel Triple negative breast cancer	Phase 2	12/31/2017 Phase 2 data due 4Q 2017.
CALA	$13.95 -0.45 (-3.13%)	CB-839 + nivolumab Renal cell carcinoma, malignant melanoma and non-small cell lung cancer	Phase 1/2	12/31/2017 Phase 1/2 enrolment commenced August 2016. Initial data due 2H 2017.
CAPR	$1.05 -0.04 (-3.67%)	CAP-1002 HOPE-Duchenne Duchenne Muscular Dystrophy (DMD)	Phase 1/2	12/31/2017 Phase 1/2 data released April 25, 2017. Noted improvement in certain measures of cardiac and upper limb function. 12-month data due 4Q 2017.
CBIO	$3.34 -0.09 (-2.63%)	CB 2679d/ ISU304 Hemophilia B	Phase 1/2	12/31/2017 Phase 1/2 completion of dosing announced June 14, 2017 with data due by the end of 2017.
CDTX	$6.48 +0.68 (+11.63%)	CD101 IV - STRIVE Candidemia	Phase 2	12/31/2017 Phase 2 initiated June 2016. Data due 4Q 2017.
CELG	$127.58 -3.68 (-2.81%)	REVLIMID - RELEVANCE Newly Diagnosed Follicular Lymphoma	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
CELG	$127.58 -3.68 (-2.81%)	REVLIMID - AUGMENT NHL-007 Relapsed or Refractory Follicular Lymphoma	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
CELG	$127.58 -3.68 (-2.81%)	Ozanimod - SUNBEAM Relapsing Multiple Sclerosis	Phase 3	12/31/2017 Phase 3 data released February 17, 2017 - primary endpoint met. Full data 2H 2017.
CELG	$127.58 -3.68 (-2.81%)	OTEZLA - BCT-002 RELIEF Behçet’s Disease	Phase 3	12/31/2017 Phase 3 data due 2017.
CELG	$127.58 -3.68 (-2.81%)	ABRAXANE - PANC-003 apact Adjuvant Therapy in Surgically Resected Pancreatic Cancer	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
CELG	$127.58 -3.68 (-2.81%)	ABRAXANE - NSCL-003 abound.sqm First-line late stage Squamous Non-small cell lung cancer (NSCLC)	Phase 3	12/31/2017 Phase data due 2017.
CELG	$127.58 -3.68 (-2.81%)	ABRAXANE - NSCL-003 abound.70+ Elderly Non-small cell lung cancer (NSCLC)	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
CELG	$127.58 -3.68 (-2.81%)	Ozanimod - RADIANCE Relapsing Multiple Sclerosis	Phase 3	12/31/2017 Phase 3 data due released May 22, 2017 - primary endpoint met, disability endpoint not met. Full data due 2H 2017.
CELG	$127.58 -3.68 (-2.81%)	OTEZLA Ulcerative Colitis	Phase 2	12/31/2017 Phase 2 data due 2H 2017. Phase 3 trial to be initiated 2018.
CELG	$127.58 -3.68 (-2.81%)	GED-0301 Ulcerative Colitis	Phase 2	12/31/2017 Phase 2 data due 2H 2017.
CELG	$127.58 -3.68 (-2.81%)	Durvalumab - FUSION Relapsed and/or refractory multiple myeloma (RRMM), myelodysplastic syndromes and AML	Phase 1/2	12/31/2017 Phase 1/2 data due 2H 2017.
CEMP	$3.00 -0.08 (-2.44%)	Taksta - Fusidic acid Refractory infections in bones and joints	Phase 2/3	12/31/2017 Phase 2/3 data due by the end of 2017.
CLRB	$1.54 +0.04 (+2.66%)	CLR 131 Various lymphoma	Phase 2	12/31/2017 Phase 2 trial initiation announced March 30, 2017. Initial data due 2H 2017.
CLSD	$7.03 -0.05 (-0.71%)	Suprachoroidal CLS-TA - HULK Diabetic macular edema (DME)	Phase 1/2	12/31/2017 Phase 1/2 enrollment completion announced April 20, 2017. Preliminary data due 2H 2017.
CPRX	$2.80 +0.03 (+1.08%)	Firdapse Congenital Myasthenic Syndromes (CMS)	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
CPRX	$2.80 +0.03 (+1.08%)	Firdapse Lambert-Easton Myasthenic Syndrome (LEMS)	Phase 3	12/31/2017 Refusal to file letter reported on February 17, 2016. Announced that enrollment had commenced in second Phase 3 trial on December 15, 2016, with data and NDA resubmission due in 2017.
CRBP	$6.00 -0.05 (-0.83%)	Anabasum (Resunab) Dermatomyositis	Phase 2	12/31/2017 Phase 2 data due 4Q 2017.
CRMD	$0.43 +0.04 (+10.33%)	Neutrolin - LOCK-IT 100 Hemodialysis patients with central venous catheters	Phase 3	12/31/2017 Phase 3 data due 2H 2018 with interim analysis possibly due 4Q 2017.
CYTK	$12.45 +0 (+0%)	Tirasemtiv - VITALITY Amyotrophic lateral sclerosis (ALS)	Phase 3	12/31/2017 Phase 3 data are due 4Q 2017.
DARE	$2.80 -0.2 (-6.67%)	CRLX301 Solid tumours - cancer	Phase 2a	12/31/2017 Phase 2a portion of Phase 1/2a trial commenced dosing June 2016. Initial data due in 2017.
DARE	$2.80 -0.2 (-6.67%)	CRLX101, in combination with LYNPARZA Solid tumors - cancer	Phase 1/2	12/31/2017 Phase 1/2 trial commenced dosing May 2016. Top-line data due 2017.
DARE	$2.80 -0.2 (-6.67%)	CRLX101 and paclitaxel Platinum-resistant ovarian cancer	Phase 2	12/31/2017 Further data due in 2017.
DBVT	$43.55 +0.12 (+0.27%)	Viaskin Peanut (REALISE) Peanut allergy	Phase 3	12/31/2017 Phase 3 completion of enrollment announced March 10, 2017. Data due 2H 2017 - possibly late 3Q or early 4Q.
DBVT	$43.55 +0.12 (+0.27%)	Viaskin Milk Cow’s milk protein allergy (CMPA)	Phase 1/2	12/31/2017 Phase 1/2 data due 2H 2017.
DBVT	$43.55 +0.12 (+0.27%)	Viaskin Peanut (PEPITES) Peanut allergy	Phase 3	12/31/2017 Phase 3 completion of enrollment announced March 10, 2017. Data due 2H 2017.
DCTH	$0.17 +0.03 (+19.14%)	Melphalan Hepatic Delivery System (Melphalan HDS) Hepatocellular carcinoma (HCC) - cancer	Phase 3	12/31/2017 CRL issued September 13, 2013. New Phase 3 initiated February 2016. Ongoing as of November 2016. Interim safety analysis due 2H 2017.
DMTX	$1.23 -0.03 (-2%)	DTX301 Ornithine Transcarbamylase (OTC) Deficiency	Phase 1/2	12/31/2017 Phase 1/2 trial initiated December 2016. Initial data due year end 2017.
DRRX	$1.64 -0.04 (-2.39%)	POSIMIR - PERSIST 3 Post-operative pain relief	Phase 3	12/31/2017 CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Enrollment originally expected to take one year but the company announced ammendments to the trial on April 7, 2016, which will result in time added to complete the trial. Noted June 22, 2017 that enrollment has been completed with top-line data due 4Q 2017.
EARS	$0.73 -0.01 (-2.03%)	AM-111 HEALOS Acute inner ear hearing loss	Phase 3	12/31/2017 Phase 3 HEALOS completion of enrollment announced June 5, 2017. Data due 4Q 2017.
EGLT	$1.11 +0.01 (+0.9%)	Egalet-002 Moderate to severe chronic pain	Phase 3	12/31/2017 Phase 3 to be completed 4Q 2017. NDA planned for 2018.
EVOK	$2.58 +0 (+0%)	Gimoti - EVK-001 Female diabetic gastroparesis	Phase 3	12/31/2017 Phase 3 data released July 2016. Primary endpoint not met. However, the company noted December 15, 2016 that following discussions with FDA regarding possible NDA submission, no new efficacy or safety study would be required, if bioequivalence criteria were met in a pharmacokinetic (PK) trial. Noted August 14, 2017 that PK trial has been initiated with data due 4Q 2017 with NDA filing to be submitted by late 2017 or early 2018.
EXEL	$26.88 +0.1 (+0.37%)	XL184 cabozantinib (CELESTIAL) Advanced hepatocellular cancer (HCC)	Phase 3	12/31/2017 Phase 3 initiated Sept 2013. Data due 2H 2017.
EYEG	$0.93 -0.02 (-2.12%)	EGP-437 Ocular inflammation and pain post cataract surgery	Phase 2b	12/31/2017 PPhase 1/2 top-line data released July 2016. Further data released December 5, 2016. Phase 2b commencement of enrollment announced August 1, 2017. Data due end of 2017.
EYEG	$0.93 -0.02 (-2.12%)	EGP-437 Non-infectious anterior uveitis	Phase 3	12/31/2017 Phase 3 enrollment to be completed 3Q 2017. Top-line data due 4Q 2017
FBIO	$4.29 -0.08 (-1.84%)	CAEL‐101 AL amyloidosis	Phase 1/2	12/31/2017 Phase 1/2 data due 2H 2017
FBIO	$4.29 -0.08 (-1.84%)	Triplex vaccine Cytomegalovirus (CMV)	Phase 2	12/31/2017 Phase 2 data due 2H 2017.
FLKS	$3.60 +0.1 (+2.85%)	FLX-787 Multiple Sclerosis	Phase 2	12/31/2017 Phase 2 data due by the end of 2017.
GALT	$1.78 -0.06 (-3.27%)	GR-MD-02 Non-alcoholic steatohepatitis (NASH) with cirrhosis	Phase 2b	12/31/2017 Phase 2b top-line data due December 2017.
GBT	$27.60 -1 (-3.5%)	GBT440 Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest	Phase 2a	12/31/2017 Phase 2a initiated November 2016. Data due 4Q 2017.
GBT	$27.60 -1 (-3.5%)	GBT440 HOPE-KIDS 1 Sickle cell disease - children age 6-17.	Phase 1/2	12/31/2017 Phase 2a initiated June 2016. Preliminary data released at European Hematology Association (EHA) - June 23, 2017. Noted July 10, 2017 that trial has been expanded to include a new single-dose cohort in children age 6 to 11 with data due by the end of 2017.
GILD	$72.34 -1.01 (-1.38%)	GS-9674 Nonalcoholic steatohepatitis (NASH)	Phase 2	12/31/2017 Phase 2 data due 4Q 2017.
GNMX	$1.33 +0.01 (+0.75%)	AEVI-002 (Anti-LIGHT mAb) Pediatric onset Crohn's disease	Phase 1/2	12/31/2017 Phase 1/2 data due around end of 2017.
GSK	$39.05 -0.19 (-0.49%)	anti-SAP mAb Amyloidosis	Phase 2b	12/31/2017 Phase 2b data likely due 4Q 2017.
GSK	$39.05 -0.19 (-0.49%)	GSK 165 Rheumatoid arthritis	Phase 3	12/31/2017 Phase 2b data due 2H 2017.
GSK	$39.05 -0.19 (-0.49%)	Nucala Chronic obstructive pulmonary disease (COPD)	Phase 3	12/31/2017 Phase 3 data due 2017.
GSK	$39.05 -0.19 (-0.49%)	GSK 166 Rheumatoid arthritis	Phase 2b	12/31/2017 Phase 2b data due 2H 2017.
GSK	$39.05 -0.19 (-0.49%)	GSK 165 Osteoarthritis	Phase 2	12/31/2017 Phase 2 data due 2H 2017.
HALO	$11.76 -0.16 (-1.35%)	PEGPH20 in combination with KEYTRUDA Non-small cell lung cancer (NSCLC)	Phase 1b	12/31/2017 Phase 1b enrolment resumed July 2016 under revised protocol. Response rate data possible by end of 2017.
IMRN	$5.70 +0.06 (+1.06%)	IMM-124E Nonalcoholic steatohepatitis (NASH)	Phase 2	12/31/2017 Phase 2 top-line data due 4Q 2017. Interim analysis July 10, 2017 showed no statistical difference with placebo.
IONS	$47.15 -0.26 (-0.55%)	IONIS-HTT Rx Huntington's Disease	Phase 1/2	12/31/2017 Phase 1/2 completion of enrollment noted June 22, 2017. Top-line data due around the end of 2017.
IRWD	$14.50 -0.42 (-2.82%)	IW-1973 Type 2 diabetes	Phase 2a	12/31/2017 Phase 2a data due 2H 2017.
IRWD	$14.50 -0.42 (-2.82%)	IW-1973 Type 2 diabetes	Phase 2	12/31/2017 Phase 2a data due 2H 2017.
KDMN	$2.30 +0.21 (+10.04%)	KD025 Idiopathic pulmonary fibrosis (IPF)	Phase 2	12/31/2017 Phase 2 data due 4Q 2017.
KDMN	$2.30 +0.21 (+10.04%)	KD025 Moderate to severe chronic plaque psoriasis	Phase 2	12/31/2017 Phase 2 first patient dosed September 2016. Data due 4Q 2017.
KITE	$126.03 -2.06 (-1.61%)	Axicabtagene ciloleucel - KTE-C19 (ZUMA-6) Refractory diffuse large B-cell lymphoma (DLBCL)	Phase 1/2	12/31/2017 Phase 1/2 initiated October 2016. Phase 1 data due 2017.
KMDA	$4.45 +0.2 (+4.7%)	Alpha-1 Antitrypsin (AAT) Pediatric patients newly diagnosed with type 1 diabetes	Phase 2/3	12/31/2017 Phase 2/3 data due 2H 2017.
KURA	$6.45 -0.05 (-0.77%)	Tipifarnib HRAS mutant solid tumors - cancer	Phase 2	12/31/2017 Phase 2 additional data due 2H 2017.
LLY	$77.80 -2.89 (-3.59%)	Flortaucipir F 18 (Tau imaging agent) Alzheimer's disease	Phase 3	12/31/2017 Phase 3 ongoing. Data due 2017 (internal readout).
LLY	$77.80 -2.89 (-3.59%)	Alimta + Keytruda (MK-3475-189/KEYNOTE-189) First-Line Non-Squamous Non-Small Cell Lung Cancer	Phase 3	12/31/2017 Phase 3 data due late 2017.
LLY	$77.80 -2.89 (-3.59%)	Abemaciclib - JUNIPER Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)	Phase 3	12/31/2017 Phase 3 ongoing. Data due 2017 (internal readout).
LOXO	$71.50 -2.69 (-3.63%)	Larotrectinib (LOXO-101) Solid tumors that harbor a TRK fusion.	Phase 2	12/31/2017 Announced 76% ORR at ASCO - June 3, 2017. Primary analysis by the end of 2017 with NDA filing late 2017 or early 2018.
MBVX	$0.48 +0.01 (+2.14%)	MVT-1075 Pancreatic, colon and lung cancers	Phase 1	12/31/2017 Phase 1 interim data due by the end of 2017.
MCRB	$13.33 -0.17 (-1.26%)	SER-287 Mild-to-Moderate Ulcerative Colitis	Phase 1b	12/31/2017 Phase 1b initiated December 2015. Completion of enrollment noted June 5, 2017. Data due 2H 2017
MDGL	$15.62 -0.3 (-1.89%)	MGL-3196 Heterozygous familial hypercholesterolemia (HeFH)	Phase 2	12/31/2017 Phase 2 top-line data due by end of 2017.
MDGL	$15.62 -0.3 (-1.89%)	MGL-3196 Non-alcoholic steatohepatitis (NASH)	Phase 2	12/31/2017 Phase 2 completion of enrollment announced August 1, 2017. Top-line data due end of 2017.
MESO	$7.41 +0.19 (+2.63%)	MSC-100-IV acute graft versus host disease (aGVHD) in children	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
MNOV	$4.96 -0.03 (-0.61%)	MN-166 Progressive multiple sclerosis (progressive MS)	Phase 2b	12/31/2017 Phase 2b final data due 2H 2017.
MRK	$61.84 -0.86 (-1.38%)	(MK-3475-189/KEYNOTE-189) First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)	Phase 3	12/31/2017 Phase 3 data due 4Q 2017.
MRK	$61.84 -0.86 (-1.38%)	Ertugliflozin Type 2 diabetes	PDUFA	12/31/2017 PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
MRNS	$2.89 -0.1 (-3.35%)	Ganaxolone Postpartum depression	Phase 2	12/31/2017 Phase 2 data due in 2H 2017.
MRSN	$15.62 +0.27 (+1.75%)	XMT1522 HER2 - breast cancer	Phase 1	12/31/2017 Phase 1 safety data due around the end of 2017.
MRTX	$5.05 +0.15 (+3.06%)	Sitravatinib plus nivolumab Non-small cell lung cancer (NSCLC)	Phase 2	12/31/2017 Phase 2 initial update due 2H 2017.
MRTX	$5.05 +0.15 (+3.06%)	Mocetinostat and durvalumab Non-small cell lung cancer (NSCLC)	Phase 2	12/31/2017 Phase 2 combination trial initiated June 2016. Update due 2H 2017.
MRTX	$5.05 +0.15 (+3.06%)	Glesatinib (MGCD265) Non-small cell lung cancer (NSCLC) patients with driver alterations in MET	Phase 2	12/31/2017 Phase 2 initiated December 2015. Enrollment ongoing - update due 2H 2017.
MRUS	$14.05 -0.6 (-4.1%)	MCLA-128 Gastric cancer	Phase 1/2	12/31/2017 Decision to support further development path expected 4Q 2017.
MTFB	$7.28 -0.02 (-0.3%)	Iclaprim - REVIVE-2 Acute bacterial skin and skin structure infections (ABSSSI)	Phase 3	12/31/2017 Phase 3 data due 4Q 2017.
NBIX	$53.12 -0.43 (-0.81%)	Elagolix Uterine Fibroids	Phase 3	12/31/2017 Phase 3 initiated by partner Abbvie in January 2016. Data due late 2017.
NLNK	$6.44 -0.09 (-1.38%)	Indoximod + chemotherapy Acute Myeloid Leukemia (AML)	Phase 1/2	12/31/2017 Phase 1/2 data due 2H 2017.
NLNK	$6.44 -0.09 (-1.38%)	Indoximod + temozolomide Glioblastoma multiforme cancer	Phase 2	12/31/2017 Phase 2 data due 2H 2017.
NLNK	$6.44 -0.09 (-1.38%)	Indoximod + gemcitabine and nab-paclitaxel Pancreatic cancer	Phase 2	12/31/2017 Phase 2 data due 2H 2017.
NVAX	$0.99 -0.02 (-2.02%)	NanoFlu vaccine Influenza	Phase 1/2	12/31/2017 Phase 1/2 data due 4Q 2017.
NVS	$83.18 -1.19 (-1.42%)	LEE011: MONALEESA-3 Breast cancer - (post-menopausal)	Phase 3	12/31/2017 Phase 3 trial completion 4Q 2017.
OCRX	$1.03 -0.02 (-1.81%)	OCR-002 Cirrhosis	Phase 2a	12/31/2017 Phase 2a trial initiation announced June 1, 2017. Top-line data due by the end of 2017.
ONCS	$0.92 -0.04 (-4.16%)	ImmunoPulse IL-12 Melanoma - cancer	Phase 2	12/31/2017 Phase 2 enrollment to commence June 2017 with data due 4Q 2017.
ONTX	$1.56 -0.09 (-5.46%)	IV Rigosertib - INSPIRE 2nd-line HR-MDS (high risk myelodysplastic syndromes)	Phase 3	12/31/2017 Phase 3 enrolling. Interim analysis due 4Q 2017. Noted August 15, 2017 that enrollment has been slower than expected.
OTIC	$18.85 -0.5 (-2.59%)	OTO-104 AVERTS-2 Ménière's disease	Phase 3	12/31/2017 Second Phase 3 trial initiated March 2016. Data due by the end of 2017.
PBYI	$80.70 -1.55 (-1.89%)	Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL Extended adjuvant treatment of early stage HER2-positive breast cancer	Phase 2	12/31/2017 Phase 2 additional data released December 8 2016 and April 4, 2017. Noted high rates of diarrhea. Additional data due 4Q 2017.
PFE	$32.95 -0.41 (-1.23%)	XTANDI (PROSPER) Non-metastatic high risk hormone-sensitive prostate cancer	Phase 3	12/31/2017 Phase 3 top-line data due later in 2017.
PFE	$32.95 -0.41 (-1.23%)	Xeljanz Psoriatic arthritis	Phase 3	12/31/2017 PDUFA date December 2017. No exact date given. December 31, 2017 noted as last possible date using guidance of "December 31". Advisory Committee Meeting August 3, 2017 voted 10-1 in favor of recommending approval.
PFE	$32.95 -0.41 (-1.23%)	Ertugliflozin Type 2 diabetes	Phase 3	12/31/2017 PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
PLX	$0.54 -0.02 (-2.79%)	OPRX-106 Ulcerative Colitis	Phase 2	12/31/2017 Phase 2 trial initiation announced November 30, 2016. Data due around the end of 2017.
PSTI	$1.18 -0.01 (-0.85%)	PLX-PAD (stem cells) Intermittent claudication, or IC	Phase 2	12/31/2017 Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due late 2017.
PTI	$2.04 +0 (+0%)	PTI-428 Cystic fibrosis	Phase 2	12/31/2017 Phase 2 28-day data due 4Q 2017.
PULM	$1.72 -0.03 (-1.44%)	PUR0200 COPD	Phase 2	12/31/2017 Phase 2 data due 4Q 2017.
RARE	$57.95 -3.39 (-5.53%)	Aceneuramic acid extended release (Ace-ER) GNE Myopathy	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
RDUS	$35.42 -1.01 (-2.78%)	Elacestrant Vasomotor symptoms	Phase 2b	12/31/2017 Phase 2b data due 2H 2017.
REGN	$464.02 -4.52 (-0.97%)	EYLEA + nesvacumab Diabetic macular edema (DME)	Phase 2	12/31/2017 Phase 2 enrollment completed 4Q 2016. Data due 2H 2017.
REGN	$464.02 -4.52 (-0.97%)	EYLEA + nesvacumab AMD - age-related macular degeneration	Phase 2	12/31/2017 Phase 2 data due 2H 2017.
RETA	$26.43 -0.3 (-1.13%)	Bardoxolone methyl - LARIAT Pulmonary hypertension due to interstitial lung disease - PH-ILD	Phase 2	12/31/2017 Phase 2 enrollment commenced January 2017. Data due 2H 2017.
RETA	$26.43 -0.3 (-1.13%)	Omaveloxolone - MOTOR Mitochondrial myopathies (MM)	Phase 2	12/31/2017 Phase 2 initial data due 2H 2017.
RETA	$26.43 -0.3 (-1.13%)	Omaveloxolone - REVEAL Metastatic melanoma	Phase 1/2	12/31/2017 Phase 1b portion of trial due 2H 2017.
RGLS	$0.87 -0.02 (-1.9%)	RG-012 Renal biopsy study in Alport patients	Phase 1/2	12/31/2017 Phase 1/2 data due year end 2017.
RGNX	$20.00 -2.15 (-9.71%)	RGX-501 Homozygous familial hypercholesterolemia (HoFH)	Phase 1/2	12/31/2017 Phase 1/2 dosing initiated - March 8, 2017. Interim data due by the end of 2017.
RIGL	$2.21 -0.06 (-2.65%)	Fostamatinib Autoimmune hemolytic anemia (AIHA)	Phase 2	12/31/2017 Phase 2 data from Stage 1 of trial by end of 2017.
RNN	$1.92 -0.03 (-1.54%)	RX-3117 Advanced bladder cancer	Phase 2a	12/31/2017 Phase 2a initial presented at ASCO June 4, 2017. Further data due later in 2017.
RNN	$1.92 -0.03 (-1.54%)	Supinoxin Triple negative breast cancer	Phase 2a	12/31/2017 Phase 2a initial data due towards the end of 2017.
RNN	$1.92 -0.03 (-1.54%)	RX-3117 Relapsed and refractory pancreatic cancer	Phase 2	12/31/2017 Updated Phase 2a data presented at ASCO GI January 20, 2017. Further data due 2H 2017.
RNN	$1.92 -0.03 (-1.54%)	Archexin Renal cell carcinoma (RCC) - cancer	Phase 2a	12/31/2017 Phase 2a second stage enrolment commenced February 2016. Noted May 4, 2017 an update due later this year.
RTRX	$23.64 +0.37 (+1.59%)	Liquid ursodeoxycholic acid (L-UDCA) Primary biliary cholangitis (PBC)	NDA Filing	12/31/2017 NDA filing due 2017
RVNC	$23.45 -0.3 (-1.27%)	RT002 - SAKURA 2 Moderate to severe glabellar (frown) lines	Phase 2	12/31/2017 Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RVNC	$23.45 -0.3 (-1.27%)	RT002 Plantar fasciitis	Phase 2	12/31/2017 Phase 2 data due 4Q 2017.
RVNC	$23.45 -0.3 (-1.27%)	RT002 - SAKURA 1 Moderate to severe glabellar (frown) lines	Phase 3	12/31/2017 Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RXDX	$9.65 -0.15 (-1.54%)	RXDX-105 Solid tumors - cancer	Phase 1b	12/31/2017 Phase 1b data update 2H 2017.
RXII	$0.60 +0.03 (+5.68%)	RXI-109-1402 Connective tissue growth factor (CTGF)	Phase 2	12/31/2017 Phase 2 final readout due 2H 2017.
RXII	$0.60 +0.03 (+5.68%)	Samcyprone - RXI-SCP-1502 Cutaneous warts	Phase 2	12/31/2017 Phase 2 early read outs due before the end of 2017.
SAGE	$81.25 -3.06 (-3.63%)	Brexanolone - SAGE-547 (202C) Postpartum Depression - moderate	Phase 3	12/31/2017 Phase 2 data due 2H 2017.
SAGE	$81.25 -3.06 (-3.63%)	SAGE-217 Major Depressive Disorder (MDD)	Phase 2	12/31/2017 Phase 2 initiation announced December 19, 2016. Part B data due 2H 2017.
SAGE	$81.25 -3.06 (-3.63%)	SAGE-217 Parkinson’s disease (PD)	Phase 2	12/31/2017 Phase 2 initiation announced December 13, 2016. Data from Part A data released May 9, 2017. Part B data due 2H 2017.
SAGE	$81.25 -3.06 (-3.63%)	SAGE-217 Postpartum depression (PPD)	Phase 2	12/31/2017 Phase 2 initiation 4Q 2016. Data due 2H 2017.
SAGE	$81.25 -3.06 (-3.63%)	Brexanolone - SAGE-547 (202B) Postpartum Depression (Severe)	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
SAGE	$81.25 -3.06 (-3.63%)	SAGE-217 Essential tremor	Phase 2	12/31/2017 Announced that screening has opened for Phase 2a trial - December 13, 2016. Data due 2H 2017.
SBPH	$13.15 -1.04 (-7.33%)	SB 9200 Hepatitis B (HBV)	Phase 2a	12/31/2017 Phase 2a initial data released May 23, 2017. Second cohort enrolling with top-line results due 4Q 2017.
SNDX	$11.09 -0.29 (-2.47%)	E2112 HR+, HER2- breast cancer	Phase 3	12/31/2017 Phase 3 PFS data due by the end of 2017.
SPPI	$9.45 -0.05 (-0.53%)	Poziotinib Non-small cell lung cancer (NSCLC)	Phase 2	12/31/2017 Phase 2 initiation announced March 30, 2017 with preliminary data due by the end of 2017.
SPPI	$9.45 -0.05 (-0.53%)	Poziotinib Breast cancer	Phase 2	12/31/2017 Phase 2 initiated March 2016. Data due by the end of 2017.
STML	$7.55 -0.3 (-3.83%)	SL-401 High Risk Myeloproliferative Neoplasms	Phase 2	12/31/2017 Phase 2 ongoing. ASH oral presentation - December 2016. Update due later in 2017.
STML	$7.55 -0.3 (-3.83%)	SL-401 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer	Phase 2	12/31/2017 Phase 2 enrollment completed - noted March 23, 2017. Update on patients enrolled in Stages 1 and 2 at EHA June 23, 2017 with top-line data from Stage 3 due 2H 2017.
STML	$7.55 -0.3 (-3.83%)	SL-401 Cancer- adult relapsed or refractory acute myeloid leukemia (AML)	Phase 2	12/31/2017 Phase 2 ongoing. ASH oral presentation - December 2016. Update due later in 2017.
SVRA	$5.57 -0.11 (-1.94%)	AIR001 Heart failure with preserved ejection fraction (HFpEF)	Phase 2	12/31/2017 Phase 2 data due 4Q 2017.
TBPH	$27.66 +0.63 (+2.33%)	Closed Triple - IMPACT COPD	Phase 3	12/31/2017 Phase 3 data due 2017.
TCON	$2.15 -0.05 (-2.28%)	TRC105 and Inlyta Renal Cell Carcinoma (RCC) - cancer	Phase 2	12/31/2017 Phase 2 initiated Dec 2014. Phase 2 data top-line PFS data due 2H 2017.
TCON	$2.15 -0.05 (-2.28%)	TRC105 Gestational Trophoblastic Neoplasia cancer	Phase 2	12/31/2017 Phase 2 planned for 2016. Data due 4Q 2017.
TCON	$2.15 -0.05 (-2.28%)	TRC102 Mesothelioma cancer	Phase 2	12/31/2017 Phase 2 initiated October 2015. Data are due in 2017.
TSRO	$109.05 -3.94 (-3.49%)	Niraparib - (QUADRA trial) Cancer - ovarian	Phase 2	12/31/2017 Phase 2 data due 2H 2017.
VKTX	$1.00 -0.03 (-2.92%)	VK5211 Acute Hip Fracture	Phase 2	12/31/2017 Phase 2 completion of enrollment announced July 12, 2017 with data due 4Q 2017.
VNDA	$16.05 -0.25 (-1.54%)	HETLIOZ (tasimelteon) Jet Lag Disorder	Phase 2	12/31/2017 Phase 2 data due in 2H 2017.
VRNA	$12.22 -0.05 (-0.41%)	RPL554 Maintenance treatment of COPD	Phase 2a	12/31/2017 Phase 2a data due 4Q 2017. Phase 2b trial planned for 2H 2017 with data due 2H 2018.
VRTX	$148.54 -2.83 (-1.87%)	CTP-656 Cystic fibrosis	Phase 2	12/31/2017 Phase 2 trial initiation announced December 21, 2016. Data due by end of 2017.
VRTX	$148.54 -2.83 (-1.87%)	Tezacaftor (VX-661) / ivacaftor Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation	Phase 3	12/31/2017 Phase 3 data due 2H 2017.
XBIT	$4.75 -0.08 (-1.46%)	Xilonix Pyoderma Gangrenosum	Phase 2	12/31/2017 Noted November 2016 that Phase 2 trial has been completed and data is being finalized. Noted mid-March 2017 that data will be available soon. No definitive timeline given. Assume some time in 2017.
XLRN	$34.44 -0.4 (-1.15%)	ACE-083 Facioscapulohumeral muscular dystrophy	Phase 2	12/31/2017 Phase 2 dosing initiation announced December 22, 2016. Initial data due late 2017.
XNCR	$20.35 -0.63 (-3.01%)	XmAb5871 IgG4-Related Disease (IgG4-RD)	Phase 2	12/31/2017 Phase 2 top-line data due in 2017.
XENT	$30.50 -0.65 (-2.09%)	RESOLVE steroid-releasing implant Recurrent sinus obstruction	PDUFA	01/07/2018 PDUFA January 7, 2018.
EIGR	$7.80 -0.2 (-2.5%)	Ubenimex - LIBERTY Pulmonary arterial hypertension (PAH)	Phase 2	01/08/2018 Phase 2 initiated July 2016. Enrollment completion announced May 15, 2017 with data due 1Q 2018 at JPM Conference - January 8-11, 2018.
LLY	$77.80 -2.89 (-3.59%)	Abemaciclib - MONARCH 1 and 2 Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer	PDUFA priority review	01/10/2018 Phase 3 data released March 20, 2017 - PFS primary endpoint met. Noted July 10, 2017 PDUFA under priority review. No exact data released. Assume 6-month review rendering a PDUFA date on or around January 10, 2018.
ONCE	$76.05 -2.91 (-3.69%)	Voretigene neparvovec (SPK-RPE65) Inherited retinal dystrophies	PDUFA priority review	01/12/2018 PDUFA date January 12, 2018 under priority review.
SGYP	$2.90 -0.09 (-3.01%)	Trulance (plecanatide) Constipation-predominant irritable bowel syndrome (IBS-C)	PDUFA	01/24/2018 Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. PDUFA date January 24, 2018.
PFE	$32.95 -0.41 (-1.23%)	Talazoparib BRCA-mutated breast cancer	Phase 3	01/31/2018 Phase 3 data due January 2018.
AZN	$29.08 -0.1 (-0.35%)	Acalabrutinib Relapsed or Refractory Mantle Cell Lymphoma	PDUFA priority review	02/01/2018 Priority Review announced August 2, 2017. Assume 6-month review rendering a PDUFA date on or around February 1, 2018.
PTLA	$53.22 -1.48 (-2.71%)	Andexanet alfa Factor Xa inhibitor reversal agent	PDUFA	02/02/2018 CRL August 17 2016. New PDUFA date February 2, 2018.
AMGN	$167.81 -3.58 (-2.09%)	XGEVA Multiple Myeloma	PDUFA	02/03/2018 sBLA filing announced April 4, 2017. Acceptance of filing announced June 19, 2017 - PDUFA February 3, 2018.
LPCN	$4.10 -0.08 (-1.68%)	LPCN 1021 Men with low testosterone (Low T)	PDUFA	02/08/2018 CRL issued June 2016. NDA resubmitted with new PDUFA February 8, 2017.
GILD	$72.34 -1.01 (-1.38%)	Bictegravir/F/TAF HIV	PDUFA priority review	02/12/2018 PDUFA date under priority review February 12, 2018.
AMAG	$16.95 -0.5 (-2.87%)	Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy	PDUFA	02/14/2018 sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review.
AERI	$54.80 +2.6 (+4.98%)	Rhopressa Glaucoma	PDUFA	02/28/2018 PDUFA date February 28, 2018. Advisory Committee planned.
OTIC	$18.85 -0.5 (-2.59%)	OTIPRIO Acute otitis externa	Phase 3	03/02/2018 Phase 3 trial met primary endpoint - January 5, 2017. PDUFA date for sNDA filing March 2, 2018.
BMY	$56.77 -0.73 (-1.27%)	Opdivo - 4 week applications	PDUFA	03/05/2018 PDUFA date March 5, 2018 for sBLA filings across all approved indications.
PFE	$32.95 -0.41 (-1.23%)	Xeljanz Ulcerative colitis	PDUFA	03/13/2018 sNDA acceptance announced July 13, 2017. Exact PDUFA date not released by company. BioPharmCatalyst estimate March 13 using 8-month timeline.
ABIO	$1.25 +0.05 (+4.16%)	Gencaro - GENETIC-AF trial Chronic Heart Failure	Phase 2b	03/31/2018 Phase 2b completion of enrollment announced August 16, 2017 - top-line data due late 1Q 2018.
ACOR	$21.80 +0.25 (+1.16%)	Tozadenant Parkinson’s disease (PD)	Phase 3	03/31/2018 Phase 3 data due 1Q 2018.
AIMT	$19.48 -0.17 (-0.87%)	AR101 Peanut Allergy	Phase 3	03/31/2018 Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due 1Q 2018.
AMAG	$16.95 -0.5 (-2.87%)	Rekynda Hypoactive sexual desire disorder (HSDD)	NDA Filing	03/31/2018 NDA filing due early 2018.
ANTH	$1.26 -0.03 (-2.33%)	Sollpura - RESULT Exocrine pancreatic insufficiency	Phase 3	03/31/2018 Phase 3 data due end of 2017 or early 2018.
ARGX	$20.35 -0.32 (-1.55%)	ARGX-113 Myasthenia gravis (MG)	Phase 2	03/31/2018 Phase 2 data due 1Q 2018.
ARNA	$20.58 -0.09 (-0.44%)	APD371 Pain associated with Crohn's disease	Phase 2	03/31/2018 Phase 2 data due year-end 2017 or 1Q 2018.
ARNA	$20.58 -0.09 (-0.44%)	Etrasimod Ulcerative colitis	Phase 2	03/31/2018 Phase 2 data due by end of 2017 or 1Q 2018.
AXON	$21.05 -0.75 (-3.45%)	Nelotanserin DLB patients experiencing REM Behavior Disorder (RBD)	Phase 2	03/31/2018 Phase 2 data due 1Q 2018.
AXSM	$4.95 -0.05 (-1%)	AXS-05 STRIDE-1 Treatment resistant depression	Phase 3	03/31/2018 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
AZN	$29.08 -0.1 (-0.35%)	Brilinta (THEMIS) Type 2 Diabetes	Phase 3	03/31/2018 Phase 3 data due 1Q 2018.
BHVN	$25.59 -0.05 (-0.2%)	BHV-4157 Trigriluzole Spinocerebellar Ataxia	Phase 2/3	03/31/2018 Phase 2b/3 enrollment commenced December 2016. Phase 2 top-line data due 1Q 2018.
CLBS	$4.30 +0.04 (+0.93%)	CLBS03 Type 1 diabetes	Phase 2	03/31/2018 Phase 2 top-line data due 1Q 2018.
CLSD	$7.03 -0.05 (-0.71%)	Suprachoroidal CLS-TA - PEACHTREE Macular edema associated with non-infectious uveitis	Phase 3	03/31/2018 Phase 3 completion of enrollment noted August 7, 2017 with preliminary data due 1Q 2018.
CORI	$7.62 -0.05 (-0.66%)	Corplex Donepezil Alzheimer's disease	Phase 3	03/31/2018 Pilot bioequivalence data due released May 11, 2017. Pivotal trial to commence fall of 2017 with preliminary data due 1Q 2018.
CORT	$14.60 -0.77 (-5.01%)	CORT125134 Cushing’s syndrome	Phase 2	03/31/2018 Phase 2 trial initiated 2Q 2016. Data due 1Q 2018.
CYTK	$12.45 +0 (+0%)	CK-2127107 Spinal muscular atrophy (SMA)	Phase 2	03/31/2018 Phase 2 initiated January 2016. Baseline data from first cohort released June 5, 2017. Cohort 2 enrollment to be completed in 2017. Data due 1Q 2018.
DERM	$23.42 +0.08 (+0.34%)	Olumacostat glasaretil (DRM01) Acne	Phase 3	03/31/2018 Phase 3 trial initiation announced January 3, 2017. Data are due 1Q 2018.
EARS	$0.73 -0.01 (-2.03%)	Keyzilen (AM-101) - TACTT3 Acute inner ear tinnitus	Phase 3	03/31/2018 Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line data 1Q 2018.
ESPR	$44.98 -3.33 (-6.9%)	Bempedoic Acid - 1002-039 Hypercholesterolemia	Phase 2	03/31/2018 Phase 2 initiation announced July 26, 2017 - data due 1Q 2018.
FGEN	$41.00 +0.25 (+0.61%)	Pamrevlumab (FG-3019) Pancreatic cancer	Phase 2	03/31/2018 Phase 2 ongoing. Data due late 2017 or 1Q 2018.
GALE	$0.34 -0.01 (-3.93%)	NeuVax in combination with Herceptin Breast cancer	Phase 2b	03/31/2018 Phase 2b enrollment due to be completed in a few weeks (noted July 12, 2017) with interim efficacy analysis due 6 months following - i.e. likely 1Q 2018.
GEMP	$8.60 +0.07 (+0.82%)	Gemcabene - INDIGO-1 Severe Hypertriglyceridemia (SHTG)	Phase 2b	03/31/2018 Phase 2b data due 1Q 2018.
GERN	$2.06 +0.02 (+0.98%)	Imetelstat - IMbarkStudy Myelofibrosis	Phase 2	03/31/2018 Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Further internal data review due 1Q 2018.
GSK	$39.05 -0.19 (-0.49%)	Dolutegravir + lamivudine (GEMINI 1) HIV	Phase 3	03/31/2018 Phase 3 trial commenced August 2016. Data likely due 1Q 2018.
GTHX	$15.63 +1.68 (+12.04%)	Trilaciclib First-line small-cell lung cancer	Phase 2	03/31/2018 Phase 2a top-line data due 1Q 2018.
GTHX	$15.63 +1.68 (+12.04%)	Trilaciclib First-line small-cell lung cancer	Phase 2	03/31/2018 Phase 2a top-line data due 1Q 2018.
GTHX	$15.63 +1.68 (+12.04%)	Trilaciclib First-line small-cell lung cancer	Phase 2	03/31/2018 Phase 2a top-line data due 1Q 2018.
GWPH	$101.51 -1.36 (-1.33%)	GWP42006 (CBDV) Epilepsy	Phase 2	03/31/2018 Phase 2 initiated May 2015. Data due late 2017 or early 2018.
IDRA	$1.71 -0.05 (-2.85%)	IMO-2125 Cancer - melanoma	Phase 2	03/31/2018 Phase 2 arm enrolling. Overall response data due 1Q 2018.
MCRB	$13.33 -0.17 (-1.26%)	SER-262 Primary Clostridium Difficile infection (CDI)	Phase 1b	03/31/2018 Phase 1b initiated July 2016. Data due early 2018.
MEIP	$2.74 -0.02 (-0.73%)	Pracinostat in combination with Vidaza High-risk Myelodysplastic Syndrome (MDS)	Phase 2	03/31/2018 Phase 2 commencement of dosing announced June 14, 2017 - data from first stage due 1Q 2018.
MYOK	$43.50 +0.8 (+1.87%)	MYK-461 - PIONEER-HCM Hypertrophic cardiomyopathy (HCM)	Phase 2	03/31/2018 Phase 2 top-line data released August 7, 2017 - primary endpoint met. Data from low dose cohort due 1Q 2018.
NBRV	$8.83 -0.54 (-5.77%)	Lefamulin - LEAP 2 Moderate to severe Community Acquired Bacterial Pneumonia (CABP)	Phase 3	03/31/2018 Phase 3 data due 1Q 2018.
OHRP	$0.60 +0.01 (+1.71%)	OHR-102 (MAKO) Neovascular (Wet) Age-related Macular Degeneration (AMD)	Phase 3	03/31/2018 Phase 3 data due early 2018.
PFE	$32.95 -0.41 (-1.23%)	Tanezumab Chronic low back pain	Phase 3	03/31/2018 Phase 3 ongoing. Estimate data due late 2017 or early 2018 using clinicaltrials.gov data.
PFE	$32.95 -0.41 (-1.23%)	Tanezumab Osteoarthritis	Phase 3	03/31/2018 Phase 3 ongoing. Estimate data late 2017 or early 2018 using clinicaltrials.gov data.
PTGX	$12.25 +0.05 (+0.4%)	PTG-100 Ulcerative colitis	Phase 2b	03/31/2018 Phase 2b initiation announced January 17, 2017. Interim futility analysis early 2018 with top-line data due 2018.
REGN	$464.02 -4.52 (-0.97%)	Praluent (alirocumab) ODYSSEY OUTCOMES Cardiovascular events	Phase 3	03/31/2018 Phase 3 data due 1Q 2018.
RXII	$0.60 +0.03 (+5.68%)	RXI-109-1501 Retinal scarring	Phase 1/2	03/31/2018 Phase 2 completion of enrollment announced June 21, 2017. Data due early 2018.
SGMO	$10.25 -0.35 (-3.31%)	SB-318 MPS Type 1	Phase 1/2	03/31/2018 Phase 1/2 trial initiated early 2017 with data due late 2017 or early 2018.
SGMO	$10.25 -0.35 (-3.31%)	SB-FIX Hemophilia B	Phase 1/2	03/31/2018 Phase 1/2 data due late 2017 or early 2018.
SGMO	$10.25 -0.35 (-3.31%)	SB-913 MPS Type 2	Phase 1/2	03/31/2018 Phase 1/2 trial initiated early 2017 with data due late 2017 or early 2018.
SMMT	$12.70 +0.17 (+1.35%)	Ezutromid Duchenne muscular dystrophy	Phase 2	03/31/2018 Phase 2 completion of enrollment announced May 15, 2017. 24-week data due 1Q 2018.
SNY	$48.08 -0.35 (-0.73%)	SAR439684 (PD-1) Cutaneous squamous cell carcinoma	Phase 2	03/31/2018 Phase 2 data due 1Q 2018.
SNY	$48.08 -0.35 (-0.73%)	Praluent (alirocumab) ODYSSEY OUTCOMES Cardiovascular events	Phase 3	03/31/2018 Phase 3 data due 1Q 2018.
SPHS	$1.86 +0.02 (+1.33%)	Topsalysin (PRX302) Localized low to intermediate risk prostate cancer	Phase 2	03/31/2018 Phase 2b six-month biopsy data for all patients in 1Q 2018 with final biopsy data due 4Q 2018.
SPPI	$9.45 -0.05 (-0.53%)	SPI-2012 (ROLONTIS) Chemotherapy-Induced Neutropenia	Phase 3	03/31/2018 Phase 3 completion of enrollment announced August 1, 2017 with top-line data due 1Q 2018.
TCON	$2.15 -0.05 (-2.28%)	TRC105 and Nexavar Hepatocellular carcinoma (HCC) - cancer	Phase 2	03/31/2018 Phase 2 dosing initiated May 2016 with data due early 2018.
VICL	$2.40 +0 (+0%)	VCL-HB01 HSV-2 Therapeutic Vaccine Genital Herpes in Adults	Phase 2	03/31/2018 Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018.
VICL	$2.40 +0 (+0%)	ASP0113 Vaccine Hematopoietic cell transplant recipients	Phase 3	03/31/2018 Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q 2018.
VTVT	$4.78 -0.17 (-3.44%)	Azeliragon - STEADFAST Mild Alzheimer’s disease	Phase 3	03/31/2018 Phase 3 initiated 2Q 2015. Part A enrollment completed September 2016. Part B enrollment completion announced June 1, 2017. Data from Part A due early 2018. Part B due late 2018
RIGL	$2.21 -0.06 (-2.65%)	Fostamatinib Immune Thrombocytopenic Purpura (ITP)	PDUFA	04/17/2018 Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. PDUFA date April 17, 2018.
KPTI	$8.15 -0.27 (-3.21%)	Selinexor - STORM Quadruple Refractory Multiple Myeloma	Phase 2b	04/30/2018 Phase 2b STORM Study Expansion data due April 2018.
AMGN	$167.81 -3.58 (-2.09%)	Erenumab Migraine	PDUFA	05/17/2018 Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
NVS	$83.18 -1.19 (-1.42%)	Erenumab Migraine	PDUFA	05/17/2018 Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
CLDX	$2.36 -0.05 (-2.08%)	Glembatumumab vedotin Metastatic triple negative breast cancers that overexpress gpNMB	Phase 2a	05/31/2018 Phase 2b enrollment to be completed by the end of September 2017. Data due 6-8 months later.
AGN	$224.77 -3.22 (-1.42%)	ATOGEPANT Prophylaxis (migraine)	Phase 2b	06/30/2018 Phase 2b top-line data due 1H 2018.
AGN	$224.77 -3.22 (-1.42%)	UBROGEPANT Acute (migraine)	Phase 3	06/30/2018 Phase 3 initiated July 2016. Data due 1H 2018.
ALRN	$11.89 -0.32 (-2.63%)	ALRN-6924 Peripheral T-cell lymphoma (PTCL)	Phase 2a	06/30/2018 Phase 2a interim data due 1H 2018.
ALXN	$134.63 -1.92 (-1.41%)	ALXN1210 Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 3	06/30/2018 Phase 3 data due 2Q 2018.
AMGN	$167.81 -3.58 (-2.09%)	ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma	Phase 3	06/30/2018 Phase 3 enrolling. Estimate data 1H 2018 using clinicaltrials.gov data.
ANAB	$21.29 +0.03 (+0.14%)	ANB020 Severe adult eosinophilic asthma	Phase 2a	06/30/2018 Phase 2a data due 1H 2018.
AVIR	$0.57 -0.02 (-3.23%)	BTA074 5% topical gel Condyloma	Phase 2	06/30/2018 Phase 2 enrollment to be completed 2H 2017 with data due 1H 2018.
AZN	$29.08 -0.1 (-0.35%)	Lynparza First-line ovarian cancer	Phase 3	06/30/2018 Phase 3 data due 1H 2018.
AZN	$29.08 -0.1 (-0.35%)	Durvalumab +/- tremelimumab (MYSTIC) Lung cancer	Phase 3	06/30/2018 Phase 3 data released July 27, 2017 - primary endpoint not met. Overall survival data due 1H 2018.
AZN	$29.08 -0.1 (-0.35%)	Durvalumab +/- tremelimumab (KESTREL) Head & neck cancer	Phase 3	06/30/2018 Phase 3 data due 1H 2018.
AZN	$29.08 -0.1 (-0.35%)	Durvalumab +/- tremelimumab (EAGLE) Head & neck cancer	Phase 3	06/30/2018 Phase 3 data due 1H 2018.
BHVN	$25.59 -0.05 (-0.2%)	Rimegepant Migraine	Phase 3	06/30/2018 Phase 3 trial initiation announced July 24, 2017 with top-line data due 1H 2018.
BMY	$56.77 -0.73 (-1.27%)	CM-651 – Opdivo + Yervoy First-line Head and Neck Cancer	Phase 3	06/30/2018 Phase 3 data due 1H 2018.
BMY	$56.77 -0.73 (-1.27%)	CM-451 – Opdivo + Yervoy First-line Small cell lung cancer (SCLC)	Phase 3	06/30/2018 Phase 3 data due 1H 2018.
BMY	$56.77 -0.73 (-1.27%)	CM-331– Opdivo Second-line Small cell lung cancer (SCLC)	Phase 3	06/30/2018 Phase 3 data due 1H 2018.
BMY	$56.77 -0.73 (-1.27%)	CM-078 – Opdivo Second-line Non-small cell lung cancer (NSCLC)	Phase 3	06/30/2018 Phase 3 data due 1H 2018.
BMY	$56.77 -0.73 (-1.27%)	CM-548 - Opdivo+SOC First-line Glioblastoma (GBM) cancer	Phase 2	06/30/2018 Phase 2 data due 1H 2018.
CLSD	$7.03 -0.05 (-0.71%)	Suprachoroidal CLS-TA - TYBEE Diabetic Macula Edema (DME)	Phase 2	06/30/2018 Phase 2 trial initiation announced July 11, 2017 with three-month preliminary data 1H 2018.
CNAT	$5.13 +0.02 (+0.39%)	Emricasan Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)	Phase 2b	06/30/2018 Phase 2b initiated May 2014. Topline data due 1H 2018.
CTIC	$3.12 -0.17 (-5.17%)	PIXUVRI - PIX306 Trial B-cell non-Hodgkin lymphoma	Phase 3	06/30/2018 Phase 3 data due 1H 2018. Noted August 2, 2017 that enrollment has completed.
EIGR	$7.80 -0.2 (-2.5%)	Ubenimex - ULTRA Secondary lymphedema	Phase 2	06/30/2018 Phase 2 dosing commenced July 2016. Enrollment to be completed 4Q 2017. Data due 2Q 2018.
ESPR	$44.98 -3.33 (-6.9%)	Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048 Hypercholesterolemia - statin intolerance	Phase 3	06/30/2018 Phase 3 initiation of efficacy trials announced January 8, 2017. Data due 2Q and 3Q 2018.
ESPR	$44.98 -3.33 (-6.9%)	Bempedoic acid (ETC-1002-040) - Clear Harmony Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins	Phase 3	06/30/2018 Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
FBIO	$4.29 -0.08 (-1.84%)	CEVA101 Severe Traumatic Brain Injury	Phase 2	06/30/2018 Phase 2 data in children due 1H 2018.
FBIO	$4.29 -0.08 (-1.84%)	Pepvax vaccine Cytomegalovirus (CMV)	Phase 2	06/30/2018 Phase 2 data due 1H 2018.
FBIO	$4.29 -0.08 (-1.84%)	IV Tramadol Post-operative Pain	Phase 3	06/30/2018 Phase 3 to be initiated in 3Q 2017 with data due 2Q 2018.
FLKS	$3.60 +0.1 (+2.85%)	FLX-787 Amyotrophic lateral sclerosis (ALS)	Phase 2	06/30/2018 Phase 2 initiated September 2016. Readout due 2017/18.
FOMX	$4.39 -0.11 (-2.45%)	FMX101 - FX2017-22 Acne	Phase 3	06/30/2018 Phase 3 data released March 27, 2017 - three of four primary endpoints met across two trials. Third Phase 3 trial to be initiated with commencement of dosing announced August 3. 2017 with data due mid-2018.
GLMD	$8.00 -0.31 (-3.74%)	Aramchol - ARREST Non-Alcoholic Steatohepatitis (NASH)	Phase 2b	06/30/2018 Phase 2b enrollment complettion announced January 9, 2017. Data due 2Q 2018.
GTHX	$15.63 +1.68 (+12.04%)	G1T38 plus Faslodex ER+ breast cancer	Phase 1b	06/30/2018 Phase 1b preliminary data due 2Q 2018.
IDRA	$1.71 -0.05 (-2.85%)	IMO-8400 Dermatomyositis	Phase 2	06/30/2018 Phase 2 initiated November 2015. Enrollment to be completed by the end of 2017 with data due 1H 2018.
JNCE	$13.35 -0.79 (-5.59%)	JTX-2011 Solid tumors - Cancer	Phase 1/2	06/30/2018 Phase 1/2 trial initiated September 2017.Phase 2 arm initiation announced April 21, 2017. Efficacy data due 1H 2018.
JNJ	$133.04 -1.13 (-0.85%)	Esketamine Treatment resistant depression	Phase 3	06/30/2018 Phase 3 ongoing. Data and regulatory filings likely due 2018.
KURA	$6.45 -0.05 (-0.77%)	Tipifarnib Chronic myelomonocytic leukemia (CMML) - cancer	Phase 2	06/30/2018 Phase 2 first dosing announced January 17, 2016 with data due 1H 2018.
KURA	$6.45 -0.05 (-0.77%)	Tipifarnib Lower risk myelodysplastic syndromes (MDS) - cancer	Phase 2	06/30/2018 Phase 2 top-line data due 1H 2018.
MACK	$1.24 -0.03 (-2.37%)	MM-141 - CARRIE Cancer - front line pancreatic cancer	Phase 2	06/30/2018 Phase 2 completion of enrollment announced June 19, 2017. Data due 1H 2018.
MDWD	$6.00 -0.3 (-4.77%)	NexoBrid Severe burns	Phase 3	06/30/2018 Phase 3 initiated mid April 2015. Data due 1H 2018.
MTNB	$1.32 -0.04 (-2.95%)	MAT2501 Non-tuberculous mycobacterium (NTM)	Phase 2	06/30/2018 Phase 2 trial to be initiated 2H 2018. Data from PK/tolerability trial due 2Q 2018.
NVCR	$19.25 -0.75 (-3.75%)	Tumor Treating Fields (TTFields) STELLAR Mesothelioma	Phase 2	06/30/2018 Phase 2 enrollment completion announced March 31, 2017. Data likely 2Q 2018.
OBSV	$7.74 +0.05 (+0.65%)	OBE001 - IMPLANT2 IVF	Phase 2	06/30/2018 Phase 2 trial did not meet primary endpoint in 2016. Phase 3 European trial initiation announced March 7, 2017. Data due 1H 2018.
OCUL	$5.84 +0.04 (+0.68%)	OTX-TP Glaucoma and ocular hypertension	Phase 3	06/30/2018 Phase 3 initiated October 2016. Data due 1H 2018.
PBYI	$80.70 -1.55 (-1.89%)	Neratinib Third-line HER2-positive metastatic breast cancer	Phase 3	06/30/2018 Phase 3 data due 1H 2018.
PRTA	$55.23 -2.46 (-4.27%)	NEOD001 PRONTO Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction	Phase 2b	06/30/2018 Phase 2b data due 2Q 2018.
RNN	$1.92 -0.03 (-1.54%)	RX-3117 in combination with Abraxane First-line pancreatic cancer	Phase 2a	06/30/2018 Phase 2 data due 2Q 2018.
RXDX	$9.65 -0.15 (-1.54%)	STARTRK-2 entrectinib Solid tumors - cancer	Phase 2	06/30/2018 Phase 2 trial initiated September 2015. Noted June 7, 2017 that enrollment will be completed 3Q 2017 with data due 1H 2018.
SBBP	$6.90 -0.1 (-1.43%)	COR-003 (levoketoconazole) - SONICS Endogenous Cushing’s syndrome	Phase 3	06/30/2018 Phase 3 completion of enrollment announced June 27, 2017 with top-line data due 2Q 2018.
SNGX	$2.09 -0.09 (-4.13%)	SGX301 (synthetic hypericin) Cutaneous T-Cell Lymphoma (CTCL) cancer	Phase 3	06/30/2018 Phase 3 data due 1H 2018.
SVRA	$5.57 -0.11 (-1.94%)	Aironite - INDIE Pulmonary hypertension (PH)	Phase 2	06/30/2018 Phase 2 enrollment to be completed 4Q 2017 with top-line data due 1H 2018.
TBPH	$27.66 +0.63 (+2.33%)	TD-9855 nOH	Phase 2a	06/30/2018 Phase 2a data due 1H 2018.
TNXP	$2.97 -0.04 (-1.33%)	TNX-102 SL Post-traumatic stress disorder (PTSD)	Phase 3	06/30/2018 Initiation of first of two Phase 3 trials announced March 28, 2017 in military-related PTSD 1Q 2017. Interim analysis due 1H 2018 with top-line data due 2H 2018.
TOCA	$12.58 +0.35 (+2.86%)	Toca 511 & Toca FC Recurrent brain cancer	Phase 2/3	06/30/2018 Data from Phase 2 portion are due 1H 2018.
VKTX	$1.00 -0.03 (-2.92%)	VK2809 Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease	Phase 2	06/30/2018 Phase 2 data due 1H 2018.
VNDA	$16.05 -0.25 (-1.54%)	Tradipitant Gastroparesis	Phase 2	06/30/2018 Phase 2 data due 1H 2018.
CELG	$127.58 -3.68 (-2.81%)	Luspatercept - BELIEVE b -thalassemia	Phase 3	07/31/2018 Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
CELG	$127.58 -3.68 (-2.81%)	Luspatercept - MEDALIST Myelodysplastic syndromes (MDS) cancer	Phase 3	07/31/2018 Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
EBIO	$1.12 -0.11 (-8.96%)	Vicinium Non-muscle invasive bladder cancer (NMIBC)	Phase 3	07/31/2018 Phase 3 enrollment to be completed 1Q 2018, with 3-month top-line data due mid-2018 and 12-month data due 2Q 2019.
FOMX	$4.39 -0.11 (-2.45%)	FMX103 Papulopustular rosacea	Phase 3	07/31/2018 Phase 2 top-line data released September 12, 2016. Endpoints met. Phase 3 trial to be initiation announced June 12, 2017 with top-line data due mid-2018.
GNMX	$1.33 +0.01 (+0.75%)	AEVI-001 (NFC-1) ADHD - 9-Gene subset	Phase 2	07/31/2018 Phase 2 trial to be initiated 2H 2017 with data due mid-2018.
LLY	$77.80 -2.89 (-3.59%)	Ramucirumab Second-line bladder cancer	Phase 3	07/31/2018 Phase 3 PFS data released May 31, 2017 - primary endpoint met. Final OS results are currently expected in mid-2018.
OBSV	$7.74 +0.05 (+0.65%)	OBE2109 - EDELWEISS Endometriosis	Phase 2b	07/31/2018 Phase 2b data due mid 2018.
RGLS	$0.87 -0.02 (-1.9%)	RG-012 - HERA Alport Syndrome	Phase 2	07/31/2018 Phase 2 interim data due mid-2018.
SCYX	$1.65 -0.06 (-3.51%)	SCY-078 - oral Vulvovaginal candidiasis (VVC)	Phase 2	07/31/2018 Phase 2 initation of dosing annunced August 3, 2017 - data due mid-2018.
VTL	$2.85 +0.05 (+1.78%)	VTI-308 Alcohol-induced liver decompensation, or AILD	Phase 3	07/31/2018 Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due mid 2018.
XLRN	$34.44 -0.4 (-1.15%)	Luspatercept - MEDALIST Myelodysplastic syndromes (MDS) cancer	Phase 3	07/31/2018 Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
XLRN	$34.44 -0.4 (-1.15%)	Luspatercept - BELIEVE b -thalassemia	Phase 3	07/31/2018 Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
PFE	$32.95 -0.41 (-1.23%)	Sutent (Sunitinib) Renal cell carcinoma (RCC)	PDUFA priority review	09/19/2018 PDUFA date January 2018. Specific date not released. BPC estimate late January. Advisory Committee Meeting September 19, 2017.
AMRN	$3.04 +0.01 (+0.33%)	Vascepa REDUCE-IT outcomes trial High Triglycerides With Mixed Dyslipidemia	–	09/30/2018 Interim analysis announced September 12, 2016 - trial to proceed. Second interim analysis August 14, 2017 also recommended trial to continue. Final data due 2Q or 3Q 2018.
AQXP	$14.48 +0.27 (+1.9%)	AQX-1125 LEADERSHIP Bladder pain syndrome/interstitial cystitis (BPS/IC).	Phase 3	09/30/2018 Phase 2 trial did not meet endpoints - June 2015 but postive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Data due 3Q 2018.
HSGX	$1.77 -0.01 (-0.73%)	NeoCart Cartilage defects in the knee	Phase 3	09/30/2018 Phase 3 completion of enrollment announced June 27, 2017. Top-line data and potential BLA filing 3Q 2018.
SBBP	$6.90 -0.1 (-1.43%)	COR-003 (levoketoconazole) - LOGICS Endogenous Cushing’s syndrome	Phase 3	09/30/2018 Phase 3 enrollment from second trial to begin 3Q 2017 with top-line data expected in 3Q 2018.
CNCE	$14.17 -0.32 (-2.21%)	AVP-786 Agitation in patients with Alzheimer's disease	Phase 3	09/30/2018 Phase 3 initiated December 2015. Trial to be completed 3Q 2018
AGN	$224.77 -3.22 (-1.42%)	Brazikumab Crohn's disease	Phase 2b	12/31/2018 Phase 2b data due 2018.
AGN	$224.77 -3.22 (-1.42%)	Cariprazine Major depressive disorder (MDD)	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
AGN	$224.77 -3.22 (-1.42%)	ABICIPAR Age-related macular degeneration (AMD)	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
AKBA	$15.02 -0.23 (-1.51%)	Vadadustat - TRILO2GY Three-times-weekly dosing regimen for vadadustat	Phase 3	12/31/2018 Phase 3 trial to be initiated 2H 2017 with data due by the end of 2018.
AKBA	$15.02 -0.23 (-1.51%)	Vadadustat - FO2RWARD Renal anemia	Phase 2	12/31/2018 Phase 2 data due by the end of 2018.
ALDX	$4.30 +0.05 (+1.17%)	ADX-102 Noninfectious anterior uveitis	Phase 3	12/31/2018 Phase 3 trial initiation announced April 27, 2017 with data due 2H 2018.
ALDX	$4.30 +0.05 (+1.17%)	ADX-102 Sjögren-Larsson Syndrome (SLS)	Phase 2	12/31/2018 Phase 3 trial initial data due 2H 2018.
ALKS	$50.92 -0.64 (-1.25%)	ALKS 3831 - ENLIGHTEN-2 Schizophrenia	Phase 3	12/31/2018 Pivotal trial initiated February 2016. Data due 2018.
ALXN	$134.63 -1.92 (-1.41%)	Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)	Phase 3	12/31/2018 Phase 3 enrollment to be completed in 2017 with data due 2018.
ANIK	$52.68 -0.29 (-0.55%)	Cingal Osteoarthritis	Phase 3	12/31/2018 Additional Phase 3 trial commenced enrollment - May 25 2017. Trial to be completed in 2018.
ARGX	$20.35 -0.32 (-1.55%)	ARGX-113 Immune thrombocytopenia (ITP)	Phase 2	12/31/2018 Phase 2 data due 2H 2018.
AZN	$29.08 -0.1 (-0.35%)	Dapagliflozin - DECLARE Type-2 diabetes	Phase 3	12/31/2018 Cardiovascular outcome data due 2H 2018.
AZN	$29.08 -0.1 (-0.35%)	Benralizumab - TERRANOVA COPD	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
AZN	$29.08 -0.1 (-0.35%)	Farxiga - DECLARE Cardiovascular Outcomes	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
AZN	$29.08 -0.1 (-0.35%)	Selumetinib - ASTRA Thyroid cancer	Phase 3	12/31/2018 Phase 3 data due 2018.
AZN	$29.08 -0.1 (-0.35%)	Roxadustat - ANDES Anaemia	Phase 3	12/31/2018 Phase 3 data due 2018.
AZN	$29.08 -0.1 (-0.35%)	PT010 Chronic obstructive pulmonary disease (COPD)	Phase 3	12/31/2018 Phase 3 data due 2018.
AZN	$29.08 -0.1 (-0.35%)	Durvalumab +/- tremelimumab (NEPTUNE) Lung cancer	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
AZN	$29.08 -0.1 (-0.35%)	Durvalumab +/- tremelimumab (DANUBE) Bladder cancer	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
AZN	$29.08 -0.1 (-0.35%)	Anifrolumab Lupus	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
BIIB	$284.42 -9.66 (-3.29%)	Raxatrigine - BIIB074 (Nav1.7 inhibitor) Painful Lumbosacral Radiculopathy (PLSR)	Phase 2	12/31/2018 Phase 2 initiated 2016. Data due in 2018.
BLPH	$1.13 +0.02 (+1.8%)	INOpulse delivery device Pulmonary Arterial Hypertension (PAH)	Phase 3	12/31/2018 Phase 3 commenced enrollment June 2016. Interim analysis and top-line data due 2018.
BLRX	$1.13 +0.01 (+0.89%)	BL-8040 Consolidation treatment for AML cancer patients	Phase 2b	12/31/2018 Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
BMY	$56.77 -0.73 (-1.27%)	CM-602 – Opdivo + Elo + SOC Myeloma	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
BMY	$56.77 -0.73 (-1.27%)	CM-238 – Opdivo (Adjuvant) Melanoma	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
CELG	$127.58 -3.68 (-2.81%)	REVLIMID - ROBUST First-line ABC Diffuse large B-cell lymphoma (DLBCL)	Phase 3	12/31/2018 Phase 3 data due 2018.
CELG	$127.58 -3.68 (-2.81%)	MM-007 OPTIMISMM Multiple Myeloma - refractory	Phase 3	12/31/2018 Phase 3 data due 2018.
CELG	$127.58 -3.68 (-2.81%)	Ozanimod - TRUE NORTH Ulcerative Colitis	Phase 3	12/31/2018 Phase 3 enrolling. Data due 2018.
CELG	$127.58 -3.68 (-2.81%)	GED-0301 (CD-003) Crohn’s disease	Phase 3	12/31/2018 Phase 3 enrolling. Data due 2018.
CELG	$127.58 -3.68 (-2.81%)	GED-0301 (CD-002) Crohn’s disease	Phase 3	12/31/2018 Phase 3 enrolling. Data due 2018.
CELG	$127.58 -3.68 (-2.81%)	Oral Azacitidine - CC-486-AML-001 Post induction AML Maintenance	Phase 3	12/31/2018 Phase 3 data due 2018.
CELG	$127.58 -3.68 (-2.81%)	ABRAXANE - IMpower 131 ( I/O Combo) Non-small cell lung cancer (NSCLC)	Phase 3	12/31/2018 Phase 3 data due 2018.
CELG	$127.58 -3.68 (-2.81%)	ABRAXANE - IMpower 130 ( I/O Combo) Non-small cell lung cancer (NSCLC)	Phase 3	12/31/2018 Phase 3 data due 2018.
CELG	$127.58 -3.68 (-2.81%)	ABRAXANE - IMPassion ( I/O Combo) Triple Negative Metastatic Breast Cancer	Phase 3	12/31/2018 Phase 3 data due 2018.
CFRX	$1.20 +0 (+0%)	CF-301 Serious infections caused byStaph aureus including MRSA	Phase 2	12/31/2018 Phase 2 initiation announced May 25, 2017 - data due 4Q 2018.
CNAT	$5.13 +0.02 (+0.39%)	Emricasan NASH cirrhosis - ENCORE-PH trial	Phase 2	12/31/2018 Phase 2b initiated November 2016. Data due 2018.
CNCE	$14.17 -0.32 (-2.21%)	CTP-543 Alopecia areata	Phase 2a	12/31/2018 Phase 2 clinical hold placed May 17, 2017 lifted July 10, 2017. Trial completion due 2H 2018.
EARS	$0.73 -0.01 (-2.03%)	AM-111 ASSENT Acute inner ear hearing loss	Phase 3	12/31/2018 Phase 3 ASSENT data due 2H 2018.
EPZM	$14.10 +0.25 (+1.8%)	Tazemetostat Adult patients with mesothelioma characterized by BAP1 loss-of-function	Phase 2	12/31/2018 Phase 2 dosing commenced August 2016. Enrollment completed June 2017 with data due 2018.
FGEN	$41.00 +0.25 (+0.61%)	Roxadustat - ANDES Anaemia	Phase 3	12/31/2018 Phase 3 data due 2018.
GEMP	$8.60 +0.07 (+0.82%)	Gemcabene - AZURE-1 Nonalcoholic steatohepatitis (NASH) / Nonalcoholic fatty liver disease (NAFLD)	Phase 2	12/31/2018 Phase 2 trial to be initiated in 2H 2017 with data due 2H 2018.
GSK	$39.05 -0.19 (-0.49%)	Closed Triple - CAPTAIN Asthma	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
GWPH	$101.51 -1.36 (-1.33%)	Epidiolex Tuberous Sclerosis Complex	Phase 3	12/31/2018 Phase 3 data due 2018.
IMGN	$6.07 -0.05 (-0.82%)	Kadcyla (KATHERINE). HER2-positive breast cancer - residual invasive disease	Phase 3	12/31/2018 Phase 3 data due in 2018.
INCY	$121.74 -2.6 (-2.1%)	Epacadostat with Keytruda - ECHO-301 Cancer - first-line metastatic melanoma.	Phase 3	12/31/2018 Phase 3 initiated June 2016. Initial data due 2018
INVA	$12.51 -0.13 (-1.03%)	Closed Triple Asthma	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
IOVA	$4.65 +0.2 (+4.49%)	LN-145 Cervical cancer	Phase 2	12/31/2018 Phase 2 dosing has commenced - noted August 16, 2017. Initial data due 2018.
JNJ	$133.04 -1.13 (-0.85%)	STELARA (USTEKINUMAB) Ulcerative colitis	Phase 3	12/31/2018 Phase 3 trial to be completed in 2018.
JNJ	$133.04 -1.13 (-0.85%)	DARZALEX (Daratumumab) Frontline multiple myeloma (non-transplant)	Phase 3	12/31/2018 Phase 3 data likely due 2018.
KITE	$126.03 -2.06 (-1.61%)	Axicabtagene ciloleucel - KTE-C19 (ZUMA-2) Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer	Phase 2	12/31/2018 Phase 2 pivotal initiated November 2015. Data due 2018.
KITE	$126.03 -2.06 (-1.61%)	Axicabtagene ciloleucel - KTE-C19 (ZUMA-3) Adult patients with r/r ALL - cancer	Phase 1/2	12/31/2018 Phase 1 data released at ASCO June 5, 2017. Complete remission 73%. Phase 2 data due 2018.
KITE	$126.03 -2.06 (-1.61%)	Axicabtagene ciloleucel - KTE-C19 (ZUMA-4) Pediatric and young adult patients with r/r ALL - cancer	Phase 1/2	12/31/2018 Phase 2 data due 2018.
KPTI	$8.15 -0.27 (-3.21%)	Selinexor - SADAL Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2b	12/31/2018 Phase 2b additional interim data released June 23, 2017 at EHA. Final top-line data due 2H 2018.
MACK	$1.24 -0.03 (-2.37%)	MM-121 Cancer - Heregulin Positive Non-Small Cell Lung Cancer	Phase 2	12/31/2018 Phase 2 initiated mid Feb 2015. Data due 2H 2018.
MBRX	$2.56 -0.09 (-3.4%)	Annamycin Acute myeloid leukemia (AML) - cancer	Phase 1/2	12/31/2018 Phase 1/2 data due 2018.
MRK	$61.84 -0.86 (-1.38%)	Epacadostat with Keytruda - ECHO-301 Cancer - first-line metastatic melanoma.	Phase 3	12/31/2018 Phase 3 initiated June 2016. Initial data due 2018.
NVS	$83.18 -1.19 (-1.42%)	QVM149 Asthma	Phase 3	12/31/2018 Phase 3 data due 2018.
NVS	$83.18 -1.19 (-1.42%)	LEE011: MONALEESA-7 Breast cancer - (pre-menopausal)	Phase 3	12/31/2018 Phase 3 trial completion 4Q 2017.
NVS	$83.18 -1.19 (-1.42%)	Entresto - PIONEER In-hospital initiation vs. enalapril following ADHF (acute decompensated heart failure)	Phase 3	12/31/2018 Phase 3 trial completion due 2018.
NVS	$83.18 -1.19 (-1.42%)	Entresto - PARAGON HF-pEF (heart failure with preserved ejection fraction)	Phase 3	12/31/2018 Phase 3 interim analysis due 2018. Filing 2019.
NVS	$83.18 -1.19 (-1.42%)	AIN457 (Cosentyx) Non-radiographic axial SpA	Phase 3	12/31/2018 Phase 3 data due 2018.
OBSV	$7.74 +0.05 (+0.65%)	OBE022 - PROLONG Pre-term labor	Phase 2a	12/31/2018 Phase 2a to commence 4Q 2017, with top line data expected around year end 2018.
PFE	$32.95 -0.41 (-1.23%)	Tanezumab Cancer pain	Phase 3	12/31/2018 Phase 3 ongoing. Estimate data due 2018 using clinicaltrials.gov data.
PLX	$0.54 -0.02 (-2.79%)	PRX-102 Fabry disease	Phase 3	12/31/2018 Phase 3 dosing commenced October 2016. Enrollment to be completed 2H 2017 with data in 2018.
RETA	$26.43 -0.3 (-1.13%)	Bardoxolone methyl - CATALYST Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH	Phase 3	12/31/2018 Phase 3 commenced enrollment October 2016 with data due 2H 2018.
RIGL	$2.21 -0.06 (-2.65%)	Fostamatinib IgA nephropathy	Phase 2	12/31/2018 Phase 2 preliminary data released January 5, 2017. Enrollment of second cohort to be completed in 2017 with data due in 2018.
SGEN	$46.37 -0.8 (-1.7%)	ADCETRIS in combination with chemotherapy - ECHELON-2 Frontline CD30-positive mature T-cell lymphomas - cancer	Phase 3	12/31/2018 Phase 3 enrollment completed November 2016. Data are due in 2018.
SVRA	$5.57 -0.11 (-1.94%)	Molgradex Autoimmune pulmonary alveolar proteinosis (PAP)	Phase 3	12/31/2018 Phase 3 data due by the end of 2018.
TBPH	$27.66 +0.63 (+2.33%)	Closed Triple - CAPTAIN Asthma	Phase 3	12/31/2018 Phase 3 data due 2H 2018.
VNDA	$16.05 -0.25 (-1.54%)	HETLIOZ (tasimelteon) Smith-Magenis Syndrome	Phase 3	12/31/2018 Phase 3 initiated 4Q 2016. Data due 2018.
CLSN	$1.35 -0.03 (-2.18%)	ThermoDox - OPTIMA Hepatocellular carcinoma - liver cancer	Phase 3	03/31/2019 Failed to meet primary endpoint. New Phase 3 trial initiated with first interim efficacy endpoint due 1Q 2019.
GSK	$39.05 -0.19 (-0.49%)	Danirixin Chronic obstructive pulmonary disease (COPD)	Phase 2b	03/31/2019 Phase 2b data likely due 1Q 2019.
PRTO	$1.30 -0.05 (-3.71%)	Vonapanitase (PRT-201) PATENCY-2 Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)	Phase 3	03/31/2019 Phase 3 enrollment to be completed 1Q 2018. Data due 1Q 2019.
XNCR	$20.35 -0.63 (-3.01%)	XmAb5871 Systemic Lupus Erythematosus (SLE)	Phase 2	03/31/2019 Phase 2 trial initiated March 2016. Initial data due 2018 or early 2019.
ABBV	$69.85 -0.57 (-0.81%)	ABBV-8E12 Progressive supranuclear palsy (PSP)	Phase 2	06/30/2019 Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: May 2019
ATNM	$0.60 +0 (+0%)	Iomab-B Hematopoietic Stem Cells Transplantation	Phase 3	06/30/2019 Phase 3 initiated June 2016. Enrollment to be completed by the end of 2018. Data due 2H 2019
BMY	$56.77 -0.73 (-1.27%)	CM-568 - Opdivo + Yervoy First-line Non-small cell lung cancer (NSCLC)	Phase 2